University of South Carolina

Scholar Commons
Theses and Dissertations
8-9-2014

An Investigation of Mitochondrial Bioenergetics and the Turnover
of Succinated Proteins in the Adipocyte during Diabetes
Ross Tanis
University of South Carolina - Columbia

Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Biology Commons

Recommended Citation
Tanis, R.(2014). An Investigation of Mitochondrial Bioenergetics and the Turnover of Succinated Proteins
in the Adipocyte during Diabetes. (Master's thesis). Retrieved from https://scholarcommons.sc.edu/etd/
2904

This Open Access Thesis is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and
Dissertations by an authorized administrator of Scholar Commons. For more information, please contact
digres@mailbox.sc.edu.

An Investigation of Mitochondrial Bioenergetics and the Turnover of Succinated Proteins
in the Adipocyte during Diabetes
By
Ross Tanis
Bachelor of Science
Michigan State University 2009

Submitted in Partial Fulfillment of the Requirements
For the Degree of Master of Science in
Biomedical Sciences
School of Medicine
University of South Carolina
2014
Accepted by:
Norma Frizzell, Director of Thesis
Edie Goldsmith, Reader
L. Britt Wilson, Reader
Lacy Ford, Vice Provost and Dean of Graduate Studies

© Copyright by Ross Tanis, 2014
All Rights Reserved
ii

Dedication
I would like to dedicate this thesis to my parent’s Robert and Marie Tanis as well as my
brother James Tanis. With their support I have always been given the opportunity to
pursue my dreams and goals. My mentor Dr. Norma Frizzell has made all of this possible
by allowing me the opportunity to pursue my Master’s Degree in her laboratory, for
which I will always be grateful.

iii

Acknowledgements
I would like to thank my mentor, Dr. Norma Frizzell, first and foremost for making this
opportunity possible and allowing me to pursue my Master’s Degree in her laboratory. I
would like to give a special thanks to Dr. Gerardo Piroli for his expertise and advice
throughout my experience in this lab. I would also like to thank our current PhD student
Allison Manuel and our former student Stani Day for teaching me new skills and
assisting me throughout the course of my work. Also, I would like to thank Hannah Faile,
our undergraduate student who I had a chance to mentor this past semester, for her
dedication and assistance.

iv

Abstract
We previously identified the chemical modification S-(2-succino)cysteine (2SC),
which is formed when the Krebs cycle metabolite fumarate reacts with protein cysteine
residues, also termed protein succination. Protein succination is increased in the
adipose tissue of ob/ob and db/db mice in vivo and in 3T3-L1 adipocytes grown in high
glucose in vitro. The increase in 2SC in the 3T3-L1 adipocyte occurs as a direct result of
glucotoxicity and increased mitochondrial stress. We have shown that uncoupling
agents, which lower mitochondrial stress, prevent the increase in succinated proteins.
In this study we examined the relationship between increased succination and
mitochondrial bioenergetics in adipocytes matured in 30 mM (high) vs. 5 mM (normal)
glucose. In addition we examined if sodium phenylbutyrate (PBA), which lowers protein
succination, might be acting as an uncoupling agent in adipocytes cultured in high
glucose. We observed that adipocytes matured in high glucose had a decreased spare
respiratory capacity, increased proton leak across the inner membrane and increased
non-mitochondrial respiration, consistent with increased mitochondrial stress. We also
determined that PBA was not acting as an uncoupling agent but instead appeared to
lower the mitochondrial respiratory protein content, thereby reducing respiration and
protein succination.
The unfolded protein response (UPR) and endoplasmic reticulum (ER) stress have
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previously been documented in the adipose tissue during diabetes and during adipocyte
maturation in high glucose. We assessed the development of ER stress in adipocytes
matured in 5 mM vs. 30 mM glucose and observed that although most ER stress markers
were unchanged with glucose concentration, the terminal ER stress marker CHOP was
consistently elevated in high glucose and this occurred in parallel with increased 2SC.
The use of PBA as a therapeutic agent for the treatment of T2DM is currently
being investigated in human subjects as it has been shown to reduce ER stress in the
adipose tissue of animal models of T2DM. We examined the effects of PBA
administration for 8 weeks in db/db mice. We observed reduced serum glucose and
reduced triglyceride (TG) levels after PBA treatment; however, there was no effect of
PBA on 2SC or ER stress markers in the adipose tissue of db/db mice. Unexpectedly, PBA
treatment increased ER stress and TG deposition in the liver of db/db mice.
Considering that 2SC is an irreversible and stable protein modification we
wanted to determine if succinated proteins could be degraded intracellularly. We
demonstrated that succinated proteins are degraded by the lysosome and are released
from the cell as a free amino acid (2SC) and bound in a peptide.
Overall, these studies have further extended our knowledge of the relationship
between mitochondrial stress, protein succination and ER stress. In addition, we have
determined the mechanism of turnover of succinated proteins in the adipocyte in vitro.
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Chapter I
General Introduction
1.1. Epidemiology of Type 2 Diabetes Mellitus
Diabetes affects 25.8 million people, or 8.3% of the population, and is the
seventh leading cause of death in the United States. There are 18.8 million diagnosed
and 7.0 million undiagnosed people with diabetes. From 2005-2008, it was estimated
that 79 million Americans had prediabetes, based on fasting blood glucose (FBG) and
hemoglobin A1c levels. Diabetes predominantly affects those aged 20 to 65 and older
but had an incidence rate of 0.26%, equivalent to 215,000 people, in 2010 for those
under age 20. The estimated cost in 2012 of treating diagnosed cases of diabetes was
$245 billion, with direct medical costs accounting for $176 billion. Further complications
of the disease such as heart disease, kidney failure, stroke and amputations continue to
exacerbate medial costs, accounting for approximately 10% of the costs associated with
treating diabetes (1).
Obesity is frequently associated with the disease and 85.2% patients diagnosed
with type 2 diabetes mellitus (T2DM) are either overweight or obese. From 2009-2010,
it was reported that 69.2% of the population was overweight or obese and a striking
35.9% classified as obese (1). With over one third of the U.S. population suffering from
obesity, it is paramount to address the economic, environmental and biological factors
that contribute to T2DM. Although many risk factors have been attributed to T2DM
1

these vary widely among populations; with African Americans, Alaska Natives, American
Indians, Hispanics/Latinos, Native Hawaiians, and Pacific Islander Americans being more
susceptible than non-Hispanic whites (1). Despite evidence of some ethnic and genetic
susceptibility, the evidence suggests physical inactivity and increased caloric intake are
the greatest risk factors for developing T2DM (2).
1.2. Obesity, Hyperinsulinemia and Insulin Resistance
T2DM is the most prevalent form of diabetes, representing 90-95% of all adult
cases of diabetes, and is a result of the body’s insensitivity to insulin concomitant with
hyperinsulinemia, hyperglycemia, and dyslipidemia (3). T2DM is commonly preceded by
prediabetes, which is characterized by elevated FBG levels ranging between 100-125
mg/dL (5.6-6.9 mM). T2DM is characterized by fasting blood glucose levels above 126
mg/dL (7 mM) and hemoglobin A1c levels above 6.5% on two separate tests (4).
Insulin is produced by the pancreatic beta cells and is released in response to
ingestion of a meal to facilitate the uptake of glucose into the peripheral tissues (5). In
T2DM, there is a loss of insulin sensitivity in the peripheral tissues, despite
hyperinsulinemia, resulting in sustained hyperglycemia (6). The insulin receptor and its
signal transduction pathway have been extensively studied providing detailed insight
into the intracellular mechanism of insulin signaling. Insulin binds to the insulin
receptor, a tyrosine kinase receptor comprised of a dimer of αβ subunits. The alpha
subunits reside on the outer leaflet of the lipid bilayer and contain the binding sites for
insulin. The beta subunits are transmembrane helices with the carboxy termini residing
in the cytosol (5). The alpha subunits inhibit the autophosphorylation of the beta
2

subunits in the absence of insulin. Upon binding of insulin, the inhibition is relieved and
autophosphorylation activity of the beta subunits permits specific tyrosine residues to
become phosphorylated. Insulin receptor substrate (IRS) proteins 1 and 2 have 20
potential phosphorylation sites that can be regulated and serve to propagate the
cascade of events induced by insulin and other growth factors. Insulin signaling appears
to be primarily mediated through IRS, which generates the second messenger
phosphatidylinositol (3,4,5)-triphosphate by activating phosphoinositide 3-kinase
leading to phosphoinositide-dependent kinase-1 (PDK1) and phosphoinositidedependent kinase-2 /mammalian target of rapamycin complex 2 (mTORC2) activation.
PDK1 and mTORC2 can phosphorylate Akt/protein kinase B (PKB) to promote cell
growth and survival (7). Akt can also promote enhanced glucose uptake and storage and
inhibit gluconeogenesis through suppression of forkhead transcription factor O1, or
Foxo1. Alternatively, the activation of mammalian target of rapamycin complex 1
mTORC1 via Akt is responsive to amino acids and promotes protein synthesis,
lipogenesis and inhibition of autophagy. Defects in the insulin signaling pathway can
result from mutations, loss of function or over/under phosphorylation giving rise to
insulin resistance (7).
As the body becomes less sensitive to insulin the pancreas continue to produce
more insulin in an attempt to compensate for the reduction in glucose uptake. However,
it has been shown that hyperinsulinemia can prevent glucose transporter type 4 (Glut4)
trafficking to the membrane, further impairing glucose uptake (7). Additionally, the
levels of IRS have been shown to be reduced, as activation of mTORC1 promotes their
3

ubiquitination and degradation. Activation of c-Jun N-Terminal kinase (JNK), a mitogenactivated protein kinase (MAPK) primarily activated by cytokines, can lead to p-IRS1
Ser307, impairing insulin sensitivity and this can be mediated by both tumor necrosis
factor alpha (TNFα) and hyperlipidemia (7, 8, 9, 10). Therefore the combined effects of
dysregulated glucose metabolism, dyslipidemia and inflammation, in addition to
individual risk, are key factors in determining the progression of the disease (11).
1.3. Symptoms and Treatment of Type 2 Diabetes Mellitus
A newly diagnosed T2DM patient will have a range of symptoms including
frequent urination, increased thirst and fatigue; which can be attributed to the elevated
FBG from impaired tissue glucose uptake. In these individuals, the initial treatment
consists of monitoring blood glucose levels in response to a pharmacological agent,
coupled with diet and exercise. Metformin is the pharmacological agent of choice that
primarily controls blood glucose levels through regulation of hepatic gluconeogenesis
(12). Thiazolidinediones and sulfonylureas are additionally used when metformin alone
does not have the efficacy to reduce blood glucose levels. Thiazolidinediones act as
peroxisome proliferator-activated receptors (PPAR) agonists, altering the expression of
genes involved in glucose and lipid metabolism (13) while sulfonylureas stimulate the
pancreas to release insulin (14). Although these drugs can help reduce hyperglycemia
there is currently no cure for T2DM. The patient’s quality of life with the disease
depends on how well they manage their blood glucose levels, which can be enhanced
through a healthy diet and regular physical activity. As the disease progresses
complications in other organs such as the eyes, kidneys and nerves can arise (15). Many
4

of these tissues have non-insulin dependent glucose uptake and therefore their
exposure to chronic hyperglycemia has been proposed to exacerbate cellular
mitochondrial dysfunction. This results in increased superoxide production (oxidative
stress) and intracellular damage in these tissues (16).
1.4 Adipocyte Metabolism in Type 2 Diabetes Mellitus
In healthy individuals the body responds to the ingestion of a meal by secreting
insulin to facilitate glucose uptake into insulin sensitive tissues. In response to nutrient
excess the adipose tissue can expand and store the surplus calories in the form of
triglycerides (TGs). The storage capacity of the adipose tissue does not exceed its limit in
healthy individuals and it contains a pool of preadipocytes that differentiate into
adipocytes in response to nutrient excess. In the obese/diabetic individual, the
hypertrophied adipocytes have lost their capacity to store excess fuel, resulting in the
storage of fat in peripheral tissues such as liver and muscle (17).
Adipose tissue is considered an endocrine organ as it secretes a range of
hormones known as adipokines. Increased or decreased production of several of these
hormones is correlated with obesity and/or T2DM. Leptin was one of the first
adipokines shown to be involved in nutrient regulation, functioning to decrease food
intake and increase energy expenditure via the central nervous system (CNS) (17).
However, despite the hyperleptinemina in obese subjects, the hormonal response in the
CNS is reduced due to leptin resistance (8). Adiponectin is also secreted from the
adipocyte and is known to act in an insulin sensitizing manner, increasing fatty acid
oxidation in the muscle and suppressing gluconeogenesis in the liver. Increased plasma
5

levels of adiponectin are associated with a decreased risk for T2DM, while decreased
levels are observed in patients with T2DM (8).
The energy stored in the form of adipocyte TGs are released as free fatty acids
(FFAs) when required as fuel for peripheral tissues. Obesity occurs due to an imbalance
in energy expenditure versus energy intake. In the obese state the white adipose tissue
(WAT) takes on a markedly different phenotype. Adipose tissue is composed of a
network of cells containing adipocytes and the stromal vascular fraction; comprised of
macrophages, neutrophils, eosinophils, and endothelial cells (17). In the subcutaneous
adipose tissue of humans with T2DM and the visceral adipose tissue of ob/ob and db/db
mice, there is increased infiltration and proliferation of macrophages (18, 19). However,
the immune response appears to be secondary to adipocyte dysfunction as
hypertrophied adipocytes release more FFAs, which in turn leads to the recruitment of
the immune cells (20). Increased circulating FFAs can also lead to deposition of FFAs in
other organs such as the liver resulting in non-alcoholic fatty liver disease (21).
As the adipose tissue expands, angiogenesis does not keep pace with growth
resulting in a hypoxic state that can lead to the induction of vascular endothelial growth
factor (VEGF) and plasminogen activator inhibitor-1 (20). Both of these cytokines can
modulate adiponectin gene expression, thereby compromising adiponectin mediated
regulation of hepatic gluconeogenesis and fatty acid oxidation by the muscle (20).
Further, in hypertrophied adipocytes, there is an increased secretion of the monocyte
chemoattractant protein-1 (MCP- 1) that attracts immune cells and inflammatory
cytokines, e.g. interleukin-6 (IL-6) and TNFα, which have been attributed to systemic
6

insulin resistance (8, 9, 20). Although adipose tissue is comprised of cell types including
adipocytes and macrophages, recent evidence suggests that adipocyte dysfunction is an
early player in the cascade of events that contributes to the development of T2DM (17).
1.5 Adipocyte Stress
Considering the burden of adipose tissue mass and the role of the adipocyte in
energy metabolism, it is critical that we understand the mechanism of adipocyte
dysfunction during the progression of diabetes. Increased metabolic flux in the
adipocyte increases cellular oxygen consumption leading to increased production of
reactive oxygen species (ROS) in T2DM (22). The production of ROS can lead to
peroxidation of lipids forming the α,β-unsaturated aldehydes 4-hydroxy and 4-oxo
trans-2,3 nonenal (23). These can react with cysteine, histidine and lysine residues to
irreversibly modify proteins by carbonylation (23). In addition to mitochondrial derived
oxidative stress, there is increased evidence of endoplasmic reticulum (ER) stress (ER
stress) in the adipocyte in diabetes (24).
It has previously been shown that the differentiation of 3T3-L1 fibroblasts (an
established cell culture model for the study of adipogenesis) into 3T3-L1 adipocytes
occurs through the induction of the unfolded protein response (UPR) and ER stress (25,
26). During adipogenesis this response assists the differentiating endocrine cell through
the up-regulation of chaperone proteins to help fold the newly synthesized proteins (25,
26). The UPR is a normal homeostatic response to the accumulation of misfolded
proteins in the ER. Upon induction of the UPR, glucose-regulated protein
78/immunoglobulin-binding protein (Grp78/BiP) dissociates from the ER membrane to
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help chaperone misfolded proteins. Oxidoreductase proteins such as protein disulfide
isomerase (PDI) can then interact with the misfolded proteins in order to catalyze
disulfide bond formation and correct folding, thereby relieving the pressure on the ER.
When there is an accumulation of newly synthesized or misfolded proteins in the ER and
chaperone mediated folding cannot keep pace and ER stress develops (25, 26).
There are three established pathways in the ER stress response (see Chapter 2,
Introduction for more details). Briefly, in the absence of ER stress, Grp78/BiP is
associated with 3 ER membrane spanning proteins: Inositol-requiring enzyme 1 (IRE1),
which splices X-box binding protein 1 (XBP-1), activating transcription factor 6 (ATF6),
and the RNA-dependent protein kinase-like ER kinase (PERK). However, during ER stress
Grp78/BiP dissociates from these 3 membrane proteins and each of them initiates signal
transduction pathways as part of the UPR. The net effect of this signaling is to cause upregulation of chaperone proteins and transient attenuation of protein translation
(Figure 1.1) (26, 27, 28).
1.6 Adipocyte Mitochondrial Stress
In parallel with oxidative and ER stress, mitochondrial stress has been
documented in adipocytes matured in high glucose and in the adipose tissue of diabetic
mice (29, 30, 31, 32). The reaction of fumarate, a Krebs cycle metabolite, with the thiol
group on protein cysteine residues forms the chemical modification S-(2succino)cysteine (2SC), also termed protein succination (Figure 1.2) (33). The levels of
succinated proteins are increased in adipocytes matured in 30 mM glucose vs. 5 mM
glucose and in the adipose tissue of diabetic mice (31, 32). Protein succination increases
8

due to mitochondrial stress in adipocytes matured in high glucose as a result of an
increase in the ATP/ADP ratio. As a result of respiratory control, the electron transport
chain is inhibited, which concomitantly increases the mitochondrial membrane potential
(ΔΨm) and the NADH/NAD+ ratio. Consequently the NAD+ dependent enzymes of the
Krebs cycle are inhibited resulting in increased fumarate and protein succination (30).
The identity of ~40 succinated proteins in adipocytes has been confirmed (34) and
further analysis of several of these has demonstrated that succination is associated with
impaired structure or function (29, 35). For example, succination of adiponectin on
cysteine 39 inhibits its polymerization into the biologically active high molecular weight
form and thus it is not secreted but retained in the adipocyte. This provides a unique
explanation for the impaired secretion and reduced circulating levels of this hormone in
diabetes (29). Additionally we have shown that PDI, an ER chaperone protein, is
succinated on an active site cysteine, thereby reducing its activity and potentially
exacerbating ER stress in diabetes (unpublished results).
In this thesis I propose that protein succination, as a direct result of
mitochondrial stress, is a unique contributor to ER stress by causing misfolded proteins
to accumulate in the ER. I expect to observe increased ER stress in adipocytes matured
in 30 mM glucose (high) vs. 5 mM (normal) glucose and I propose that chemical agents
that reduce protein succination will lead to a decrease in ER stress. By demonstrating
that reducing protein succination relieves ER stress, I hope to identify a new mechanism
by which glucotoxicity contributes to adipocyte dysfunction.
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Figure 1.1: ER stress pathway. Protein misfolding in the ER induces the UPR. There are 3
signaling arms of the UPR that are activated upon increased protein misfolding:
activation of (1) IRE1 leads to spliced (s) (XBP-1) and (2) ATF6 which leads to
transcriptional up-regulation of chaperone proteins. The third arm involves PERK, which
oversees the attenuation of nascent protein translation via phosphorylation of
eukaryotic initiation factor 2 alpha (eIF2α). Further, activation of ATF4 leads to
transcriptional up-regulation of CCAAT/enhancer binding protein (C/EBP) homologous
protein (CHOP) (27), a terminal response to ER stress (28).

10

Figure 1.2: Formation of 2-(S-succino)cysteine (2SC). The reaction of fumarate with
cysteine residues on proteins to form 2SC (33).
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Figure 1.3: Glucotoxicity Driven Mitochondrial Stress increases Protein Succination.
Increased extracellular glucose concentrations contribute to mitochondrial stress as
increased metabolism increases the ATP/ADP ratio. Accumulation of ATP inhibits the
electron transport chain, increasing the mitochondrial membrane potential (ΔΨ m) and
the NADH/NAD+ ratio, consequently inhibiting the NAD+-dependent enzymes of the
Krebs cycle. Inhibition of the Krebs cycle enzymes increases fumarate concentrations,
allowing free protein thiol groups on cysteine residues (PrSH) to react with fumarate
forming succinated proteins (Pr-2SC) (34).
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Chapter II
Adipocyte Mitochondrial Metabolism and ER Stress
2.1. Introduction
The 3T3-L1 adipocyte model is a widely accepted model for the study of
adipocyte function in obesity and diabetes (36). These studies are frequently conducted
in the presence of high glucose concentrations (25-30 mM), as many cell lines are
commonly maintained under these conditions. However, recent reports have
documented that extracellular glucose concentrations have a significant impact on the
measurement of mitochondrial bioenergetics (37), which is of importance for
experimental conditions examining mitochondrial function in diabetes. While several
studies have examined adipocytes cultured in both 5 mM (normal) and 25-30 mM (high)
glucose (38, 39, 40) the majority of published studies appear to be conducted in high
glucose medium. The Seahorse Extracellular Flux Analyzer (XF) 24 allows for the
measurement of the oxygen consumption rate (OCR) in a respiring cell. In addition, the
use of several chemical compounds that interfere with respiratory chain components
allows assessment of several parameters of mitochondrial function. These include basal
respiration, ATP synthesis coupled to oxygen consumption, proton leak (using
oligomycin), spare respiratory capacity (SRC) (using an uncoupler e.g. carbonyl cyanide
4-(trifluoromethoxy) phenylhydrazone (FCCP)) and non-mitochondrial respiration (NMR)
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(using rotenone/antimycin A) (Figure 2.1) (41). We hypothesized that adipocytes
matured in 30 mM glucose versus 5 mM glucose would have an increased OCR and
produce more ATP coupled to oxygen consumption. In addition, a recent report by Han
et al. suggested that the majority of oxygen consumption in the cell was attributable to
NMR (22). We wanted to investigate these claims as we have observed increased
mitochondrial stress in the 3T3-L1 adipocyte (30, 31). Our overall aim was to compare
the mitochondrial bioenergetic profile of adipocytes matured in 5 mM glucose (normal
glucose) versus 30 mM glucose (high glucose).
The process of adipogenesis involves a change in phenotype from either a
fibroblast (in vitro) or a preadipocyte (in vivo) into an adipocyte (17). When adipocytes
are matured in high glucose, adipogenesis is accompanied by activation of the UPR as
these cells change phenotype (25, 26). UPR driven increases in chaperone proteins can
assist in the folding of newly synthesized proteins destined for secretion from the
adipocyte. When the UPR is initiated, Grp78 dissociates from monomeric protein kinase
RNA-like endoplasmic reticulum kinase (PERK), which is embedded in the ER membrane.
This particular arm of the UPR has recently been confirmed as the most important
signaling arm in adipocytes undergoing adipogenesis (25, 26). PERK then homodimerizes
and is activated by autophosphorylation. Eukaryotic initiation factor α (eIF2α) is then
phosphorylated by PERK at Ser-51 leading to an attenuation of protein translation. This
response transiently relieves the cell from the burden of accumulating proteins (26).
Downstream of p-eIF2α the activating transcription factor 4 (ATF4) translocates to the
nucleus and up-regulates CCAAT/enhancer binding protein (C/EBP) homologous protein
14

(CHOP). The up-regulation of CHOP leads to the induction of growth arrest and DNA
damage-inducible protein (GADD34), causing dephosphorylation eIF2α and restoration
of cellular protein synthesis (Figure 1.1) (42). However, prolonged induction of CHOP is
also associated with terminal ER stress and the induction of cellular apoptosis Figure
2.2) (27, 42-46).
Several studies have shown that the UPR and ER stress occur during
adipogenesis in both high glucose (25 mM or 30 mM) and high insulin (25, 26). However,
these conditions are not ‘normal’ and are instead comparable to diabetic conditions.
Therefore, we hypothesized that activation of the UPR was only occurring as a result of
the diabetic culture conditions and we predicted that cells matured in 5 mM (normal
glucose) would not have an up-regulated UPR or ER stress response. To test the
relationship between high glucose/insulin and UPR activation we compared adipocytes
matured in 5 mM glucose/0.3 nM insulin (normal conditions) versus 30 mM glucose /3
nM insulin (diabetic conditions). We examined markers of adipocyte differentiation to
ensure that the 3T3-L1 fibroblasts had undergone a phenotypic change into an
adipocyte. We also assessed UPR/ER stress markers throughout the course of adipocyte
maturation to compare the effects of the different glucose/insulin conditions.
2.2. Results
The respiratory profile of 3T3-L1 adipocytes matured in high glucose (30 mM)
conditions has been described previously (23), however these conditions correspond to
what could be considered a hyperglycemic, hyperinsulinemic environment and are not
appropriate ‘control’ conditions for the study of normal adipocyte respiration. The
15

Seahorse XF24 was used to contrast the OCR of adipocytes after 2 days maturation (M2)
in either 5 mM or 30 mM glucose. The glucose/insulin concentrations used were 5
mM/0.3 nM and 30 mM/3 nM to reflect concentrations similar to normal post-prandial
conditions and a hyperglycemic/hyperinsulinemic state, respectively. A representative
trace is shown in Figure 2.3A, illustrating the basal bioenergetic profile of adipocytes
followed by ATP synthase inhibition (oligomycin), membrane depolarization with FCCP
and complex I/complex II inhibition (rotenone/antimycin A), as denoted by the arrows.
There was ~1.7-fold increase in the basal respiration and ~1.8-fold increase in ATP
synthesis coupled to oxygen consumption in adipocytes grown in high glucose (gray
bars) vs. normal glucose (black bars) (***p<0.001, Figure 2.3B). Proton leak and NMR
were also significantly increased in high glucose (**p<0.01, Figure 2.3B). However, the
SRC, a measure of the cellular capacity to increase mitochondrial respiration under
stress, was ~2.4-fold lower in high glucose vs. normal glucose (***p<0.001, Figure 2.3B).
Several studies have described ER stress as a requirement for 3T3-L1 fibroblasts to
undergo differentiation into 3T3-L1 adipocytes using high glucose and high insulin
conditions (25, 26). To determine if only high glucose could induce ER stress we
conducted adipocyte maturation in normal or high glucose/insulin and assessed several
markers of both adipogenic differentiation and the UPR/ER stress. The production of
adiponectin and PPARγ confirmed that the 3T3-L1 fibroblasts (F) had differentiated and
matured into adipocytes in both 5 mM and 30 mM glucose during the 11 day time
course (3 days differentiation (D) in 30 mM glucose followed by 8 days in 5 mM/0.3 nM
or 30 mM/3 nM glucose/insulin maturation medium (M1-M8), Figure 2.4A). Notably,
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adipocytes matured in 30 mM glucose had decreased total adiponectin levels vs. those
cultured in 5 mM glucose towards the end of maturation (M7 and M8) (Figure 2.4A&B,
lanes 16-23). Markers of the UPR and ER stress were upregulated in adipocytes as they
begin maturation in either normal or high glucose. Grp78 increased throughout
maturation in normal and high glucose, with a peak level occurring in 5 mM glucose at
M5 (Figure 2.3C). PDI, endoplasmic reticulum oxidoreductin-1-like protein (Ero1-Lα) and
p-eIF2α were most pronounced during days M1-5 of maturation in both normal and
high glucose and declined thereafter until day M8 (M1-M8, Figure 2.4A, Lanes 4-23).
Concomitant with a decrease in p-eIF2α levels there was a pronounced increase in CHOP
levels in adipocytes, but notably this was only in the cells matured in 30 mM glucose
(Figure 2.4A&E). Consistent with previous results (29, 31), the post-translational
modification 2SC increased in adipocytes matured in 30 mM glucose for up to 8 days
(M2-M8, lanes 8-23), and interestingly appeared to increase in parallel with CHOP levels
(Figure 2.4A). In addition to the observed decrease in adiponectin detected in Figure 2.4,
the adipocytes matured in 30 mM glucose secreted increased levels of proinflammatory cytokines, including TNFα, VEGF and MCP-1 (Figure 2.5A-C) versus those
matured in 5 mM glucose. Taken together, these results confirm that increased protein
succination occurs in parallel with increased ER stress (CHOP), decreased adiponectin
production and elevated pro-inflammatory cytokine production when adipocytes are
matured in high glucose conditions.
Recent work has suggested that insulin alone is sufficient to increase ER stress in
adipocytes and adipose tissue (47, 48). Considering that our 5 mM glucose adipocytes
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are cultured in 0.3 nM insulin and our 30 mM glucose adipocytes are cultured in 3 nM
insulin, we investigated if the combined increases in 2SC and CHOP that we observed
were due to either the glucotoxicity or the high insulin concentration. To do this we
examined ER stress and protein succination in the absence/presence of 10 nM insulin
with both 5 mM and 30 mM glucose. As observed in Figure 2.6, the addition of insulin
leads to increased protein succination in adipocytes matured in 30 mM glucose (lanes 712) and has no effect on the levels of protein succination in adipocytes matured in 5 mM
glucose (lanes 1-6), therefore it appears that combined glucotoxicity and elevated
insulin are required to observe this biomarker of mitochondrial stress. Grp78 levels
were measured to assess UPR activation and suggested that insulin leads to the
induction of the UPR (lanes 1-3 vs. 4-6 or lanes 7-9 vs. 10-12), independent of glucose
concentration. We then measured CHOP levels, and observed a pronounced increase in
CHOP in 30 mM glucose with an added response in the presence of insulin. However,
CHOP was unchanged in 5 mM glucose with or without insulin (Figure 2.6), indicating
that both high insulin and glucotoxicity are necessary for the maximal induction of
CHOP.

2.3. Discussion
The differentiation of 3T3-L1 fibroblasts into adipocytes has been extensively
studied (36), with adipocyte maturation commonly occurring in 25 mM (~450 mg/dL)
glucose and insulin concentrations ranging from 10-1700 nM (23, 48), well beyond the
physiological range. In this study, we compared adipocytes matured in 5 mM
glucose/0.3 nM insulin or 30 mM glucose/3 nM insulin to better reflect normal and
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diabetic conditions, respectively. We examined the respiratory profile of adipocytes that
had matured in 5 mM or 30 mM glucose for 2 days and observed that the adipocytes
matured in 30 mM glucose had a ~1.7-fold increase in the basal respiration rate (Figure
2.3A&B). In contrast, the spare respiratory capacity, a measure of mitochondrial
capacity to increase the rate of oxygen consumption, was ~2.4-fold lower in high
glucose versus normal glucose. This data indicates that adipocytes matured in high
glucose conditions are already respiring close to their maximal capacity and are not
optimal for use as ‘healthy’ controls for normal adipocyte function. Recent reports have
suggested that 3T3-L1 adipocytes predominantly consume oxygen in non-mitochondrial
pathways (22). However, our OCR measurements allowed us to assess both
mitochondrial and non-mitochondrial oxygen consumption as they included a final
rotenone/antimycin A inhibition of Complex I/III, effectively inhibiting mitochondrial
respiration. Our data demonstrate that non-mitochondrial respiration accounts for
~22% of the OCR (Figure 2.3B, NMR). This indicates that while non-mitochondrial
respiration is significant, it is not the major source of oxygen consumption in the 3T3-L1
adipocyte model. ATP production coupled to oxygen consumption was increased in high
glucose (Figure 2.3B, ATP) confirming our previous observations of an increased
ATP/ADP ratio in adipocytes cultured in 30 mM glucose (30).
Recently, Valsecchi et al. highlighted the importance of glucose concentration for
the study of mitochondrial (dys)function. They noted that primary cultures in the
presence of high glucose do not show differences in ROS measurements that are
observed when the same cells are cultured in normal glucose. Moreover, immortalized
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cell lines that are frequently used to study mitochondrial function in high glucose have
high glycolytic activity, rather than a dependence on mitochondrial metabolism (37).
Additionally, increased proton leak in adipocytes matured in 30 mM glucose suggests
there may be inner mitochondrial membrane damage or electron slippage (49). We
have demonstrated that there are significant differences in the mitochondrial
respiratory profile of adipocytes matured in 5 mM and 30 mM glucose. Adipocytes
matured in high glucose are consuming more oxygen and therefore produce more ATP
and have increased NMR and proton leak. This suggests that adipocytes matured in 30
mM glucose are not healthy controls as it appears their mitochondria are working closer
to their maximal capacity and may have impaired electron transport chain complexes or
integrity (49).
We investigated if UPR/ER stress during adipogenesis (25, 26) was unique to cells
cultured in high glucose or if the UPR and ER stress were still increased when cells were
cultured in 5 mM (normal) glucose. As shown in Figure 2.4A, both adipocytes cultured in
normal or high glucose proceed through differentiation (D) and maturation (M) normally
as indicated by the significant increase in PPARγ and adiponectin. Several markers of
the UPR including Grp78, PDI and p-eIF2α were increased, confirming that UPR
activation is actually a normal component of 3T3-L1 adipogenesis (25, 26), not only in 30
mM glucose but also in 5 mM glucose. Although there were subtle changes in UPR
markers between 5 mM and 30 mM glucose at various time points, these changes were
not significant (Figure 2.4A-D), but CHOP, a downstream marker of ER stress, was
significantly increased as maturation progressed, most notably in 30 mM glucose (Figure
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2.4A&E, M2-M8). Interestingly, as CHOP levels increased in 30 mM glucose this was
associated with an increase in protein succination, a biomarker of mitochondrial stress
(Figure 2.4A, anti-2SC). The increase in CHOP and succinated proteins corresponded to a
decrease in total adiponectin levels at days M7 – M8 in 30 mM vs. 5 mM glucose (Figure
2.4A) and was also associated with an increase in the release of the pro-inflammatory
markers TNF-α, MCP-1 and VEGF into the medium (Figure 2.5A-C). Han et al. have also
demonstrated that adipocytes matured in 25 mM glucose have increased adipocytederived factors such as serum amyloid A and hyaluronan that facilitate monocyte
recruitment and adhesion (40). This evidence suggests that glucose has intrinsic effects
on the adipocyte that lead to metabolic stress and cellular dysfunction. Taken together,
this data confirms that UPR activation is a normal aspect of 3T3-L1 adipogenesis and
activation; however the sustained increase in CHOP is associated with mitochondrial
stress, protein succination, and adipocyte inflammation and is unique to high glucose
culture conditions (glucotoxicity).
Increased CHOP levels have classically been associated with the induction of
apoptosis during ER stress (42, 43, 44, 45), however, our data suggests that CHOP may
be increased independent of an apoptotic response, as there was no increase in cleaved
caspase-3 at this stage of maturation (data not shown). Many recent reports have
described alternative functions of CHOP unrelated to apoptosis, e.g. Han et al. have
demonstrated that CHOP induction can inhibit adipogenesis in 3T3-L1 fibroblasts and
mouse embryonic fibroblasts (MEFs) (26). Han et al. have also identified CHOP
transcription binding sites in genes involved in protein synthesis such as tRNAs and
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initiation factors. Interestingly, no apoptotic genes were found to be directly associated
with transcriptional activation by CHOP (27). In C57BL/6J mice, CHOP was shown to
suppress transcription of metabolic genes in the liver during ER stress (50), providing
further evidence that CHOP is more promiscuous than once thought and its role is not
limited to apoptotic events. This suggests that CHOP signaling is dependent on the
nature of the stress signal and that the presence of CHOP in the cell is not necessarily
indicative of an apoptotic response.
To determine whether the glucose or the insulin was the inducer of ER stress, we
matured adipocytes in 5 mM or 30 mM with and without 10 nM insulin. We observed
that insulin induced the UPR in both 5 mM and 30 mM glucose by upregulating Grp78
protein levels, but only high glucose and high insulin combined led to ER stress and
mitochondrial stress as observed by CHOP and succinated protein levels, respectively
(Figure 2.6). This confirms our earlier result indicating that adipocytes matured in high
glucose are not healthy controls and are already under a state of stress, highlighting the
importance of both glucose and insulin conditions for the study of mitochondrial
bioenergetics and ER stress in the context of diabetes research.
Overall, the direct correlation between succination and CHOP levels raises the
interesting possibility that mitochondrial stress and 2SC may have a role in sustained
CHOP signaling. Kelch-like ECH-associated protein 1 (Keap1) has recently been described
as a negative regulator of CHOP in adipocytes (51) and we have shown that Keap1
cysteines are succinated in fumarate hydratase deficient fibroblasts (52). We
hypothesize that increased succination of Keap1 may promote CHOP stability to allow
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sustained CHOP signaling, independent of ER stress, and this is the subject of ongoing
investigations in our laboratory.
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Figure 2.1. Schematic of bioenergetic profile generated from the Seahorse XF24. The
bioenergetic profile of a respiring cell can be generated using the Seahrose XF24. The
oxygen consumption rate (OCR) allows for the measurement of basal respiration, ATP
production coupled to oxygen consumption, spare respiratory capacity (SRC), proton
leak, and non-mitochondrial respiration (NMR) can be measured following the addition
of specific chemical inhibitors as denoted by the arrows (41).
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Figure 2.2 ER stress leads to apoptosis via upregulation of CHOP. ER stress leads to the
induction of CHOP (See Figure 1.1 for more details) and cellular caspases ultimately
leading to apoptosis (46).
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Figure 2.3 A & B: Bioenergetic profile of 3T3-L1 adipocytes in 5 mM and 30 mM
glucose. (A) The respiratory profile of adipocytes cultured in 5 mM (black squares/black
bars) or 30 mM glucose (gray squares/gray bars) was measured after 2 days maturation
using the Seahorse XF24 Analyzer as described in the Materials and Methods. Drugs
were added at the indicated arrows to assess mitochondrial function. (B) Basal, ATP
production (ATP), spare respiratory capacity (SRC), proton leak (H+ leak), and nonmitochondrial respiration (NMR) were measured following the addition of oligomycin
(O), FCCP (F), and rotenone/antimycin A (R/A) respectively. Data are representative of
n=4 measurements expressed as means ± S.D. Asterisks indicate statistical significance
determined by an unpaired Student t test (**P<0.01 and ***P<0.001 for 30 mM glucose
(gray bars) vs. 5 mM glucose (black bars). A Mann-Whitney Rank Sum Test was
performed on data not normally distributed.
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Figure 2.4 A: Adipogenesis proceeds via ER stress in normal or high glucose. (A) Time
course detailing markers of adipogenic differentiation and UPR/ER stress in adipocytes
cultured 5 mM (normal) or 30 mM (high) glucose. Total cell lysates (20 μg protein) from
adipocytes harvested at the indicated time points were separated by 1-D PAGE.
Adipogenic proteins and UPR/ER stress markers were detected as described in the
Materials and Methods. F represents fibroblasts, D represent cells undergoing
differentiation and M represents the maturation period in days in either 5 mM or 30
mM glucose. A representative Coomassie is shown as a loading control.
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Figure 2.4 B-C: Adipogenesis proceeds via ER stress in normal or high glucose.
Quantification of band densitometry in Figure 2.3A for adipocytes matured in 5 mM
(black circles) or 30 mM (gray circles) glucose. (B) Adiponectin. (C) p-eIF2α. (D) Grp78.
(E) CHOP.
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Figure 2.5: Increased secretion of inflammatory markers in high glucose. Secreted
levels of pro-inflammatory cytokines as measure by mouse obesity ELISA as described in
the Materials and Methods. (A) TNFα. (B) VEGF. (C) MCP-1. Data are representative of
n=4 measurements expressed as means ± S.D. Asterisks indicate statistical significance
determined by an unpaired Student t test (**P<0.01 and ***P<0.001 for 30 mM glucose
(gray bars) vs. 5 mM glucose (black bars)).

29

Figure 2.6: Insulin induces the UPR while added glucotoxicity activates the ER stress
response. 3T3-L1 adipocytes were matured in either 5 mM or 30 mM glucose for 8 days
in the absence/presence of 10 nM insulin. Protein, 20 μg, was separated by 1-D PAGE
and 2SC, Grp78 (UPR) and CHOP (ER stress) were detected as described in Materials and
Methods.
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Chapter III
Is sodium phenylbutyrate a mitochondrial uncoupler?
3.1. Introduction
There are two types of adipose tissue found in mammals, white adipose tissue
(WAT) and brown adipose tissue (BAT), both of which are responsive to insulin and can
store TGs (53). WAT is the predominant form of AT in humans making up the bulk of fat,
while BAT is a specialized tissue that plays a more prominent role in thermogenesis. BAT
expresses uncoupling protein-1 (UCP-1) which is located in the mitochondria and can
uncouple oxygen consumption from ATP synthesis, thereby dissipating the
mitochondrial membrane potential and releasing energy in the form of heat (17). This
effect of uncoupling AT has received attention as a possible therapeutic mechanism for
weight loss, as it was first documented in the early 1900’s that consumption of 2,4dinitrophenol (DNP) led to weight loss. However, DNP is also known to be carcinogenic
and is no longer clinically recommended for weight loss (54).
Using an in vitro model there are several chemicals that can be used as
depolarization agents to study the effects of dissipating the ΔΨm. These include FCCP,
carbonyl cyanide 3-chlorophenylhydrazone (CCCP) and DNP. These chemicals act as
uncouplers by carrying a proton from the mitochondrial matrix across the inner
membrane and consuming oxygen without producing ATP. Addition of an uncoupler to a
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respiring cell will depolarize the ΔΨm, leading to an increase in the OCR as the protons
are carried across the inner membrane without simultaneous production of ATP. We
have previously shown that treatment of 3T3-L1 adipocytes with CCCP or salicylic acid
(SA) (acting as a mild uncoupler) decreases the ΔΨm (30). Therefore, we were interested
in examining other agents that may also be acting as chemical uncouplers as we
predicted that they would lead to a decrease in mitochondrial stress and consequently
protein succination. We had observed that 3T3-L1 adipocytes treated with 1 mM
sodium phenylbutyrate (PBA) for 8 days during maturation had reduced protein
succination and a reduced ΔΨm. In other studies, PBA is currently being explored as a
possible therapeutic agent for the treatment of ER stress in adipose tissue (55).
However, considering that PBA and SA are similar in structure (Figure 3.1) and that SA
has been shown to act as a mitochondrial uncoupler (56), we hypothesized that PBA
may also be acting as a mitochondrial depolarization agent.
3.2. Results
PBA has been shown to lower ER stress in 3T3-L1 adipocytes matured in high
glucose (25); therefore we examined the effect of PBA on mitochondrial stress and
protein succination. As demonstrated in Figure 3.2A, adipocytes matured in high glucose
have increased levels of 2SC compared to adipocytes matured in normal glucose for 8
days. When treated with 1 mM PBA for 8 days, the levels of 2SC in adipocytes matured
in high glucose are significantly reduced and remain unchanged in normal glucose
(Figure 3.2A). Next, we measured the ΔΨm using a mitochondrial membrane permeable
dye. CCCP was used as a positive control as this uncoupler has been shown to reduce
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the levels of protein succination (30). In Figure 3.2B, CCCP reduced the ΔΨm (***P<0.001)
as expected, however, PBA treatment also reduced ΔΨm ~60% (***P<0.001) compared to
untreated 30 mM glucose adipocytes.
PBA has also been documented to inhibit adipogenesis in vitro (25). We also
observed a significant reduction in PPARγ, the master regulator of adipogenesis, after
treatment with 1 mM PBA (Figure 3.3A). Adipocyte triglyceride content was decreased
in a dose dependent manner after 2 and 8 days of PBA treatment versus 30 mM glucose
alone (*P<0.05, Figure 3.3B&C). We next quantified the extracellular glucose
concentrations in order to determine if PBA altered glucose uptake into the adipocyte.
There was a significant amount of glucose remaining in the medium after 2 days of
treatment with 1 mM PBA (***P<0.001, Figure 3.3D) versus untreated cells.
Considering the reduction in ΔΨm observed after PBA treatment (Figure 3.2A),
we hypothesized that PBA may be acting as a mitochondrial depolarization agent. Using
the Seahorse XF24, we compared the ability of PBA to decrease the ΔΨm and
subsequently increase the OCR versus FCCP or SA. FCCP uncoupled oxidative
phosphorylation at previously titered micromolar concentrations, as demonstrated by
the rapid increase in the OCR (Figure 3.4A, black/solid triangles, first arrow denotes
addition of FCCP). We have previously shown that SA reduces both the ΔΨm and the
levels of 2SC-modified proteins in adipocytes matured in high glucose (30). Here, we
confirmed that SA is acting as a mild uncoupler as increasing concentrations of SA
depolarized the inner mitochondrial membrane leading to successive increases in the
OCR (gray circles, Figure 3.4A, arrows denote addition of SA). In contrast, increasing
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concentrations of 1 mM, 5 mM and 10 mM PBA (Figure 3.4A, black circles, arrows
denote addition of PBA) did not appear to increase the OCR above the basal rate (Figure
3.4A), although the marginal increase was statistically significant with 10 mM PBA
(***P<0.001, Figure 3.4B). As the affects after acute PBA treatment were minimal, we
next examined the OCR after treatment with 1 mM or 5 mM PBA for 2 days.
Interestingly, the basal OCR was significantly reduced in adipocytes matured in 30 mM
glucose treated with 1 mM and 5 mM PBA (red circles vs. black triangles, red circles vs.
green triangles Figure 3.4C, striped and checked bars vs. gray bars, basal respiration,
***

P<0.001, Figure 3.4D). Other bioenergetic parameters such as oxygen-coupled ATP

synthesis and NMR were significantly reduced with 5 mM PBA treatment compared to
adipocytes matured in 30 mM glucose (*P<0.05, Figure 3.4D). Proton leak was
significantly reduced with 1 mM and 5 mM PBA treatment compared to adipocytes
matured in 30 mM glucose alone (***P<0.001, Figure 3.4D). Notably, 1 mM PBA
preserved the ability of the adipocytes to respond to FCCP uncoupled respiration,
whereas 5 mM PBA reduced the SRC (***P<0.001, Figure 3.4D). PBA treatment reduced
both the adiponectin and the PPARγ content in the adipocytes, highlighting that PBA
reduces markers of adipogenesis as early as 2 days (Figure 3.5A). As expected PBA
treatment lowered the UPR as noted by reductions in calreticulin, PDI and p-eIF2α
levels, particularly with 5 mM PBA. However, we observed that both CHOP cleaved
caspase-3 levels were significantly increased in the presence of 5 mM PBA (Figure 3.5A),
indicating that elevated PBA concentrations actually induce ER stress and lead to
apoptosis. This was consistent with our observation that 5 mM PBA mildly reduced cell
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viability (data not shown). Although PBA treatment did not reduce the mitochondrial
DNA copy number (Figure 3.5B), there was a reduction in the protein levels of several
mitochondrial proteins including succinate dehydrogenase (SDHA) and NADH
dehydrogenase [ubiquinone] iron-sulfur protein 4 (NDUFS4, a component of
mitochondrial complex I), versus the 30 mM glucose controls (Figure 3.5A), suggesting
that PBA may selectively lower the levels of some mitochondrial proteins.
3.3. Discussion
Protein succination appears to be a biomarker of adipocyte dysfunction and
increases as a consequence of mitochondrial stress. The increase in fumarate is
associated with an increased ATP/ADP ratio, elevated ΔΨm and increased NADH/NAD+
(Figure 1.3) and this can be reduced after treatment with CCCP, a mitochondrial
depolarization agent (30). To determine if mitochondrial stress and ER stress were
linked, we treated adipocytes with 1 mM PBA and observed a significant reduction in
succination and also the ΔΨm (Figure 3.2A&B). We hypothesized that PBA may be acting
as a depolarization agent, given that there was a reduction in the ΔΨm upon treatment
of adipocytes in 30 mM glucose with PBA (Figure 3.2B). Using the Seahorse XF 24 we
added PBA to respiring adipocytes to determine if it had an acute effect on increasing
the OCR. In contrast to known uncouplers such as FCCP and SA, we did not observe an
appreciable increase in the OCR with 1 mM or 5 mM PBA (Figure 3.4A), confirming that
PBA was not acting as an uncoupler at low doses. Although 10 mM PBA increased the
basal OCR, it is not a tolerable dose as 5 mM PBA increased the levels of caspase-3 in
adipocytes after 2 days treatment. Rather, when the adipocytes were treated with PBA
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for 2 days we noted a decrease in the basal OCR and ATP production coupled to oxygen
consumption (Figure 3.4C&D), which is consistent with the decrease in the ΔΨm. After
further investigation we observed a reduction in the mitochondrial protein content, as
noted by a decrease in SDHA and NDUFS4, but there was no change in the
mitochondrial copy number (Figure 3.5A&B). Despite the reduction in the mitochondrial
protein content with 1 mM PBA, the mitochondria still had the ability to increase the
SRC when challenged with an uncoupler (Figure 3.4D, SRC). Additionally, basal
respiration was decreased with 1 mM PBA treatment but ATP synthesis coupled to
oxygen consumption remained unchanged, which may be attributed to decreased
proton leak and enhanced membrane integrity (49). We also observed that PBA reduced
glucose uptake by the adipocyte (Figure 3.3D), suggesting that the OCR may be reduced
in part due to reduced metabolic flux (Figure 3.4D), providing further explanation for the
decrease in mitochondrial protein content without a decrease in the SRC when 30 mM
glucose is present. This is in contrast to in vivo studies using ob/ob mice where PBA was
shown to reduce blood glucose levels after just 4 days of treatment, suggesting that it
facilitates glucose uptake in an animal model of obesity (57). However, another report
indicated that PBA had no effect on blood glucose in other models of diabetes such as
the alloxan-induced diabetic mice or the Goto-Kakizaki rat (58). Therefore, it will be
necessary to determine if PBA alters hyperglycemia in diabetic humans as cellular and
animal models do not appear to show consistent effects.
PBA has been described as a chemical chaperone that can alleviate ER stress in
the liver of ob/ob mice and the adipose tissue of ob/ob and high fat diet fed mice (25,
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57). Basseri et al. further characterized PBA as an agent that can inhibit adipogenesis in
vitro (25). In keeping with these results, we observed a decrease in PPARγ and
adiponectin when adipocytes were treated with PBA (Figure 3.3A and 3.5A). Consistent
with inhibition of adipogenesis, there is a dose dependent reduction in TG levels when
adipocytes are treated with PBA during days 0-2 of maturation (Figure 3.3B&C). The UPR
was also reduced by PBA as noted by the decrease in calreticulin and p-eIF2α (Figure
3.5A) but interestingly CHOP levels increased with PBA treatment.
ER stress induced production of CHOP has previously been linked with the
induction of apoptosis (42-45) but recent reports have demonstrated CHOP also
regulates adipogenesis (25) and it up-regulates genes involved in the UPR (27). More
importantly, this study demonstrated that CHOP does not bind to promoter regions of
genes involved in apoptosis, but instead found that CHOP bound to promoter regions of
genes involved in protein synthesis, such as tRNAs and initiation factors. However,
through forced production of CHOP, they demonstrated that premature restoration of
protein synthesis could lead to cell death through the production of ROS and ATP
depletion, suggesting that there is a delicate balance between the pro and antiapoptotic CHOP actions within the cell (27). This is also supported by the increased
levels of CHOP and cleaved caspase-3, a marker of cellular apoptosis, that we observed
with 5 mM but not 1 mM PBA (Figure 3.5A). Taken together, our data indicate that PBA
may inhibit adipogenesis in vitro through the forced production of CHOP, but that higher
concentrations of PBA (>1 mM) further increase CHOP levels and may lead to cell death
if ER stress is relieved before cellular homeostasis is restored.
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Overall, while in vitro data suggest that there may be a therapeutic window for
PBA, careful consideration must be taken when treating cells with PBA as ER stress is
ultimately a protective response and premature relief from ER stress can initiate
apoptotic events. In addition, enabling adipose expansion and the recruitment
preadipocytes is a plausible therapeutic strategy for T2DM. However, our in vitro data
suggest PBA might not be beneficial as it reduced the protein levels of PPARα and
adiponectin leading to impaired adipogenesis.
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Figure 3.1 Chemical structure of sodium salicylate (SA) and sodium phenylbutyrate
(PBA).
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Figure 3.2: PBA reduces mitochondrial stress and 2SC levels. (A). Adipocytes were
matured in 5 mM or 30 mM glucose with or without 1 mM PBA for 8 days. Total protein
was harvested and 30 μg of protein was separated by 1-D PAGE and probed with anti2SC polyclonal antibody to detect protein succination. (B) Adipocytes cultured in 5 mM
glucose, 30 mM glucose or 30 mM glucose + 10 µM CCCP or 1 mM PBA for 2 days were
loaded with the dye JC-1 to measure the ΔΨm. After 20 min the cells were washed and
fluorescence was measured at Ex/Em 550/600 nm and Ex/Em 485/535 nm, as described
in Materials and Methods. The ΔΨm is expressed as a ratio of fluorescence at 600/535
nm. Data are representative of n=4 measurements expressed as means ± S.D. Asterisks
indicate statistical significance determined by a one way ANOVA using Tukey’s post hoc
test (***P<0.001 for 30 mM glucose vs. 30 mM + CCCP or PBA).
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Figure 3.3: PBA reduces lipid content in adipocytes over the time course of
maturation. (A) Adipocytes were matured in 5 mM or 30 mM glucose with or without 1
mM PBA. Total protein was harvested and 30 μg protein separated by 1-D PAGE and
probed with anti-PPARγ. (B) Adipocytes were treated with PBA on days 0-2 (C) and days
0-8 of maturation. The triglyceride content was measured as described in the Materials
and Methods. (D) The medium was collected after 2 days maturation and glucose
content was measured as described in the Materials and Methods. The results are
expressed as mean ± SD, n=4. Asterisks indicate statistical significance determined a One
Way ANOVA (***p<0.001, **p<0.01 and *p<0.05 for 30 mM glucose vs. 30 mM glucose +
PBA). A Kruskal-Wallis One Way Analysis of Variance on Ranks using Dunn’s method for
data not normally distributed.

41

Figure 3.4: PBA reduces mitochondrial respiration in 30mM glucose. (A) To test
whether or not PBA acted as a mitochondrial uncoupler, the Seahorse Extracellular Flux
Analyzer (XF) 24 was used to measure effects on respiration when PBA is added acutely
during the assay. FCCP (1.25 µM) served as a positive control and was only injected once
(first arrow). PBA was injected into the wells on 3 occasions indicated by the arrows
(black circles), at concentrations 1 mM, 5 mM and 10 mM PBA. SA was added to
demonstrate the effects of a mild-uncoupler (gray circles) and was injected into the
wells on 3 occasions indicated by the arrows at concentrations of 1 mM, 2 mM and 5
mM. (B) Fold-change increase of the basal oxygen consumption rate after the drugs
were added, ***P<0.001 for 5 mM glucose vs. FCCP and SA, n=5. (C) The respiratory
profile of adipocytes cultured in 5 mM (blue circles) and 30 mM (red circles) glucose or
30 mM with 1 mM (black triangles) or 5 mM (green triangles) PBA treatment on days 0-2
of maturation was measured using the Seahorse XF24 as described in the Materials and
Methods. Drugs were added at the indicated arrows to assess mitochondrial function.
(D) Fold-change in basal respiration, ATP production, SRC, proton leak, and nonmitochondrial respiration (NMR) were measured following the addition of oligomycin,
FCCP and rotenone/antimycin A respectively. The results are expressed as a mean ± SD,
n=5. Asterisks indicate statistical significance determined by a One Way ANOVA with a
Tukey’s post-hoc test (***P<0.001 and *P<0.05 for 30 mM glucose vs. 30 mM glucose + 1
mM or 5 mM PBA). A Kruskal-Wallis One Way Analysis of Variance on Ranks was
performed when the data were not normally distributed.
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Figure 3.5: PBA reduces ER stress and inhibits adipogenesis. (A) 3T3-L1 adipocytes
matured in 5 mM glucose or 30 mM glucose +/- 1 mM or 5 mM PBA were harvested
after 2 days of maturation. Protein (20 µg) was separated by 1-D PAGE and markers of
adipogenesis, UPR/ER stress and mitochondrial metabolism were detected as described
in the Materials and Methods. (B) DNA was isolated and mitochondrial content was
measured as described in the Materials and Methods, n=6. A One Way ANOVA using a
Tukey’s post-hoc test and a Kruskal-Wallis One Way Analysis of Variance on Ranks for
data not normally distributed.
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Chapter IV
Sodium Phenylbutyrate Treatment in db/db Mice
4.1. Introduction
The db/db mouse is a widely used model to study obesity and T2DM. There is a
point mutation in the gene encoding the leptin receptor, rendering the receptor
ineffective at binding its substrate hormone, leptin. Db/db mice have increased body
weight at birth compared to heterozygotes, display hyperinsulinemia starting at 10-14
days after birth and hyperglycemia by 4-8 weeks (59). We have previously used this
mouse model to examine protein succination in diabetes and have demonstrated that
db/db mice have increased levels of 2SC in the adipose tissue compared to control
animals (29, 32).
Previous experiments examining the effects of PBA in diabetic mice were
conducted in the ob/ob mouse model and high-fat diet fed mice (25, 57). As we have
previously used the db/db mouse, we were interested in determining whether or not
PBA could reduce mitochondrial stress and protein succination in the adipose tissue of
this model. We have shown that PDI is succinated on an active site residue and has
reduced activity (unpublished results) which could promote ER stress by causing
misfolded proteins to accumulate. Additionally, adiponectin is succinated on cysteine
39, preventing the normal incorporation of the monomer into trimers and higher
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molecular weight species that can be secreted from the cell (29). Therefore, we
hypothesized that if PBA could reduce mitochondrial stress and succination in db/db
mice, this may ultimately lower ER stress by preventing the succination of chaperone
and/or ER processed proteins. Considering that insulin resistant and obese humans are
known to have increased adipose tissue ER stress (48), we anticipated that our studies
might demonstrate the therapeutic effects of PBA as a potential T2DM treatment.
4.2. Results
We administered PBA to 7 week old db/db mice for 8 weeks to assess whether or
not the drug could limit adipose tissue dysfunction and reduce 2SC accumulation. The
drug was administered in the drinking water of at a dosage of 1 mg/g body weight
(BW)/day for the first 4 weeks and reduced to 0.5 mg/g BW/day for the remaining 4
weeks.
As expected, Figure 4.1A demonstrates that db/db mice had significantly higher
fasting blood glucose levels throughout the 8 weeks of the study compared to control
mice (##P<0.01

###

P<0.001, Figure 4.1A). PBA had no effect on the FBG levels of control

mice receiving PBA treatment (Figure 4.1A). In db/db mice, there was a trend for PBA
treatment to lower FBG but this was only statistically significant at weeks 2 through 6
(*P<0.05,

**

P<0.01,

***

P<0.001 n=6, Figure 4.1A) due to the variability in FBG.

Throughout the 8 week course of the study, db/db mice had a significantly higher body
weight than control mice (###p<0.001, Figure 4.1B). PBA had no effect on the body
weight of db/db mice whereas control mice receiving PBA treatment had a significantly
higher body weight only after 7 weeks of treatment ($p<0.05, Figure 4.1A).
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A regular chow diet was given ad libido. The amount of food consumed by the
db/db mice was greater than the amount consumed by control mice, Figure 4.2A;
although statistical analyses are not available as we housed 3 mice per cage. The db/db
mice receiving PBA treatment tended to consume less food during the early weeks 1-5,
~7 g/day when compared to the untreated db/db mice who consumed ~9 g/day (Figure
4.2A). Food consumption was not different for any of the control mice throughout the
study, with both groups consuming ~4-5 g/day. Water consumption was similar
between control mice, ~0.2-0.3 mL/day/BW. The db/db (-)PBA mice consumed ~0.4-0.6
mL/day/BW (Figure 4.2B) whereas the db/db (+)PBA mice consumed ~0.2-0.3
mL/day/BW , similar to control mice (Figure 4.2B). The dosage of PBA in the water was
reduced by 50% after 4 weeks treatment to ensure that the db/db (+)PBA mice were not
drinking less water due to a dislike or ill effect of the drug.
We assessed whole body composition of the mice at 14 weeks of age (after 7
weeks of PBA treatment) using a Dual Energy X-ray Absorptiometry (DEXA) scan. Db/db
mice had greater total lean mass, fat mass and % fat compared to control mice
(###p<0.001, Figure 4.3A). There were no differences in lean mass, fat mass or % fat with
or without PBA treatment in the db/db groups (Figure 4.3A). Interestingly, we
documented decreased lean mass and increased % fat in the control mice that received
PBA treatment compared to the untreated control mice (*p<0.05, Figure 4.3A). Upon
sacrifice, we removed the epididymal fat pads from the animals and observed a
significant increase in the mass of the fat pad from the db/db mice compared to control
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mice (###p<0.001, Figure 4.3B), but no change was observed between db/db (-)PBA and
db/db (+)PBA mice (Figure 4.3B).
To assess insulin sensitivity, we performed an insulin tolerance test after 7 weeks
of PBA treatment. Insulin was injected intraperitoneally and blood glucose was
measured over the course of 120 minutes. There was no difference in the response to
insulin observed in the control mice with or without PBA treatment (Figure 4.4). There
was a slight but significant reduction in the blood glucose levels of the db/db (+)PBA
after 120 minutes compared to db/db (-)PBA (*p<0.05, Figure 4.4).
As PBA has been shown to reduce TG levels in ob/ob mice (57) we measured TG
content in the serum of overnight fasted mice. TG levels ranged from 50-90 mg/dL in
control mice and were elevated in db/db (-)PBA mice to ~150 mg/dL beginning at 9
weeks of age (Figure 4.5A). Db/db (+)PBA mice had significantly reduced TG levels, ~5075 mg/dL, compared to db/db (-)PBA mice (*P<0.05,

**

P<0.01 and

***

P<0.001, db/db

(+)PBA vs. db/db (-)PBA, Figure 4.5A) throughout the course of PBA treatment. We then
examined the TG content in the liver and observed ~5-fold increase in db/db (-)PBA
versus control mice (###P<0.001 db/db, Figure 4.5B). Surprisingly, there was ~1.6-fold
increase in TG levels in db/db (+)PBA compared to db/db (-)PBA mice (*P<0.05, Figure
4.5B).
We have previously shown that PBA can reduce the levels of protein succination
in 3T3-L1 adipocytes (Figure 3.2A). There is increased succination in epididymal adipose
tissue of in db/db (-)PBA and db/db (+)PBA vs. control mice at 15 weeks of age (8 weeks
post treatment) (Figure 4.6, anti-2SC). We did not observe a reduction in the levels of
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succinated proteins in the db/db (+)PBA compared to the db/db (-)PBA mice (Figure 4.6).
The adipogenic marker PPARγ was increased in db/db (-)PBA and db/db/+)PBA mice
versus control and was unaltered by PBA treatment. PDI is moderately increased and
there is a pronounced increase in CHOP protein levels in db/db mice versus control. This
was unchanged by PBA treatment (Figure 4.6). Grp78 was decreased in db/db (-)PBA
mice compared to control, and was increased db/db (+)PBA mice. Overall, PBA did not
appear to have any significant effects on protein succination or the UPR/ER stress
proteins in the epididymal adipose tissue of db/db mice.
Previous studies have shown that the liver has reduced TG levels, improved
insulin signaling and decreased ER stress in ob/ob mice upon PBA treatment (57). In the
liver tissue of the db/db (-)PBA and db/db (+)PBA mouse we detected increased PDI and
CHOP levels but decreased Grp78 compared to control mice (Figure 4.7). Considering
the significant increase in liver TG levels in db/db (+)PBA mice, we examined several
proteins involved in fatty acid synthesis. The levels of phospho-acetyl-CoA carboxylase
(p-ACC) were unchanged between control and db/db (-)PBA mice but the db/db (+)PBA
mice had increased levels of p-ACC compared to both groups. Fatty acid synthase (FAS)
was increased in db/db mice versus control (Figure 4.7) but no difference was observed
in the protein levels with PBA treatment.
4.3. Discussion
PBA has been documented to reduce ER stress and blood glucose levels in
several rodent models of obesity and diabetes (25, 57). We chose to study the effects of
PBA in the db/db mouse model of diabetes as we have previously demonstrated
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increased levels of protein succination in the suprarenal, subcutaneous and epididymal
adipose tissue of these mice at 15 weeks age (32). In addition, activation of the UPR and
ER stress have been documented in the liver and adipose tissue of db/db mice (60, 61).
As we have shown that adiponectin (29) and PDI (unpublished results) are succinated in
the adipose tissue of db/db mice, we hypothesized that PBA might reduce protein
succination, thereby reducing ER stress and improving adipose homeostasis in db/db
mice.
We observed a significant reduction in blood glucose levels in db/db (+)PBA mice
after 2 weeks of PBA treatment, lasting until week 6 (Figure 4.1A). While there was a
trend for FBG to be lower in the db/db (+)PBA mice for the duration of the study, we
reduced the concentration of PBA from 1 mg/g/day to 0.5 mg/g/day after 4 weeks of
treatment over concerns regarding water consumption volumes. This change in dose
may have contributed to the lack of a significant effect in FBG by weeks 7 and 8 of
treatment. There was a trend for mice treated with PBA to have increased body weight
compared to untreated mice (Figure 4.1B) and this is a documented side effect of the
drug in humans (62). There was a trend for less food to be consumed by db/db (+)PBA
mice in the first 4 weeks of the study but the amount of food consumed/day after 8
weeks was similar between the two groups, indicating that any trend for increased
weight gain cannot be attributed to an increase in food consumption (Figure 4.2A).
Water intake was monitored to ensure that the mice were receiving the correct drug
dosage. We observed a significant reduction in the amount of water consumed in db/db
(+)PBA mice during the first 4 weeks of the study compared to db/db (-)PBA mice (Figure
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4.2B), therefore, we reduced the dosage of the drug appropriately to eliminate the
possibility that any differences we observed were due to the effects of dehydration.
Surprisingly, db/db (+)PBA mice consumed ~50% less water than db/db (-)PBA mice
while control mice consumed the same amount of water throughout the 8 week
treatment whether not PBA was present in their drinking water. As the drug
concentration was adjusted weekly based on the body weight of the mice, by week 8 of
treatment, the control (+)PBA mice were receiving a more concentrated solution of PBA
water than the db/db (+)PBA mice. This suggests the reduced water consumption by the
db/db (+)PBA mice was not related to taste, although PBA is known to have a bitter
taste.
We assessed whole body composition at 14 weeks of age (7 weeks treatment)
and did not observe any changes in lean mass, fat mass or % fat in db/db mice with or
without PBA treatment. Surprisingly, control (+)PBA mice had significantly higher % fat
and decreased lean mass compared to control (-)PBA (Figure 4.5A). As we did not
observe any differences in FBG, serum TG levels or food/water consumption between
control mice with or without PBA treatment, we did not initially examine the epididymal
or liver tissue in the treated controls. However, we are planning to analyze these tissues
in the future as PBA may be having select effects on control mice.
Non-alcoholic fatty liver disease is often associated with T2DM because
increased serum TG levels and lipoprotein imbalances result in the uptake, synthesis and
oxidation of free fatty acids by the liver (63). Although we observed a significant
reduction in serum TG levels in db/db (+)PBA mice compared to db/db (-)PBA mice
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(Figure 4.5A), there was an unexpected increase in TG levels in the liver tissue (Figure
4.5B). We next examined the lipogenic protein levels to determine if lipogenesis was
more active after PBA treatment, explaining the increase in TGs. It was found that
regulation of the first step of fatty acid synthesis by p-ACC was unchanged between
control and db/db (-)PBA mice but FAS was increased in db/db (-)PBA mice (Figure 4.7),
suggesting that the fatty liver in db/db mice at 15 weeks is associated with up-regulation
of FAS (64). We also found that p-ACC levels were increased in db/db (+)PBA mice
compared to db/db (-)PBA mice, which suggests that there would have been less TG
deposition as ACC catalyzes the first step in fatty acid biosynthesis (Figure 4.7). Further
examination of other components of the lipogenic pathway may be necessary to
determine what is contributing to increased triglycerides in liver. Additionally the 15
week time point at which we looked at these enzymes may be too late and only offers
limited insight into the regulation of TG accumulation which may have occurred at an
earlier time point. (50).
Our in vitro data in 3T3-L1 adipocytes demonstrated that 1 mM PBA treatment
for 8 days can reduce the levels of protein succination in adipocytes matured in 30 mM
glucose (Figure 3.2A). As a result, we had hypothesized that PBA would reduce protein
succination and thereby alleviate ER stress in db/db mice. Protein succination was
unaffected in the epididymal adipose tissue after 8 weeks in db/db (+)PBA mice (Figure
4.6). We did not observe any difference in adipogenesis as noted by the master
regulator of adipogenesis, PPARγ, in db/db (+)PBA. The protein levels of UPR or ER stress
markers as indicated by PDI and CHOP were elevated in db/db mice but were
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unchanged by PBA treatment (Figure 4.6). This is a surprising result as db/db mice have
increased ER stress in the adipose tissue and that PBA was able to lower ER stress in and
high fat diet fed mouse and ob/ob mouse (25, 57).
Overall, PBA reduced blood glucose levels and serum TGs in db/db mice, but
increased the deposition of TGs in the liver – a negative metabolic outcome. The UPR
and ER stress responses were unaffected by PBA treatment in the adipose tissue, which
contrasts with the results of Ozcan et al. in ob/ob mice (57). However, this could be due
to differences in the duration of the experiment, 8 weeks vs. 20 days, and/or age of
mice at sacrifice, 15 weeks vs. 10-11 weeks (57). Our results thus far in the db/db model
do not support the notion that PBA may be therapeutically useful in treating T2DM.
Indeed our surprising finding that PBA increased deposition of TGs in the liver of db/db
mice warrants further investigation of the negative effects of PBA.
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Figure 4.1: Effects of PBA treatment effects on fasting blood glucose and body weight.
Control and db/db mice were treated with or without 1 mg/g BW/day for the first 4
weeks then reduced to 0.5 mg/g BW/day for the remaining 4 weeks of the study. (A)
Fasting blood glucose was measured from the tail vein after an overnight fast. (B) Body
weights were taken once per week in the morning after an overnight fast. Data are
representative of n=5-6 mice expressed as means ± S.D. Data were subjected to a Two
Way Repeated Measures ANOVA (One Factor Repetition) to test for significance
($P<0.05 for control (-)PBA vs. control (+)PBA and ###P<0.001 for Db/db vs. control).
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Figure 4.2: Effects of PBA treatment of food consumption and water intake. Food and
water consumption were given ad libido to the mice. Control and db/db mice were
treated with PBA in the drinking water at a dosage of 1 mg/g BW/day for the first 4
weeks then reduced to 0.5 mg/g BW/day for the remaining 4 weeks of the study. (A)
Food consumption and (B) water intake were measured bi-weekly. Data are
representative of n=2-3 mice per cage.
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Figure 4.3: Effects of PBA treatment on body composition. (A) Mice were subjected to
a DEXA scan at 14 weeks of age (7 weeks +/- PBA treatment) to assess fat and lean body
mass. (B) At the time of sacrifice, epididymal fat pads were removed and weighed. Data
are representative of n=5-6 mice expressed as means ± S.D. Data were subjected to a
One-way ANOVA using Tukey’s post hoc test to test for statistical significance
(###P<0.001 for db/db vs. control).
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Figure 4.4: PBA Treatment improves insulin sensitivity. At 14 weeks of age (7 weeks -/+
PBA treatment) mice were fasted for 4 hours and then given an injection of 2U insulin
intraperitoneally. Blood glucose was measured from tail vein bleeds over the course of
120 minutes. Data are representative of n=5-6 mice, expressed as means ± S.D. Data
were subjected to Two Way Repeated Measures ANOVA (One Factor Repetition) to test
for statistical significance (*P<0.05 for db/db (-)PBA vs. db/db (+)PBA).
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Figure 4.5 PBA reduces serum triglyceride levels but increases liver triglyceride levels.
Mice were fasted weekly for 12-16 hours overnight and tail vein blood was collected. (A)
Triglyceride levels in serum of overnight fasted mice. (B) A portion of the liver was used
for triglyceride analysis and the results are expressed relative to the protein content.
Data are representative of n=5-6 mice, expressed as means ± S.D. Asterisks indicate
statistical significance as determined by a (A) Two Way repeated measure ANOVA and
(B) a One Way Tukey’s post hoc test (**P<0.01 and ***P<0.001 for db/db (-)PBA vs. db/db
(+)PBA and #P<0.05, ##P<0.01 and ###P<0.001 for db/db (-)PBA vs. control).
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Figure 4.6 PBA does not reduce ER Stress in epididymal adipose tissue of db/db mice.
Analysis of succinated proteins and ER stress markers in epididymal adipose tissue of
control and db/db mice at 15 weeks of age (8 weeks +/- PBA treatment). Protein was
separted by 1-D PAGE and 100 μg was used for the detection of 2SC using polyclonal
anti-2SC antibody and 60 μg was used for the detection of Grp78, PDI (UPR) and CHOP
(ER stress) proteins. Molecular weights are shown in kDa (left) and β-Tubulin is shown to
demonstrate protein loading.
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Figure 4.7 PBA does not alter the ER stress response but increases the inhibition of
ACC. Analysis of UPR and ER stress proteins in control and db/db mice at 15 weeks of
age Proteins, 40 μg, was separated by 1-D PAGE for the detection of Grp78, PDI (UPR)
and CHOP (ER stress) and lipogenesis markers. Molecular weights are shown in kDa (left)
and a Coomassie is shown to demonstrate protein loading.
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Chapter V
The Turnover of Succinated Proteins
5.1. Introduction
In the cell there are two protein degradation pathways for the removal of
damaged or unwanted proteins, the ubiquitin proteasome system (UPS) and the
lysosomal degradation system (also referred to as autophagy) (Figures 5.1 & 5.2) (65,
66). Protein degradation is a regulated process that responds to remove damaged
proteins and organelles or to provide amino acids in response to changes in the cellular
nutrient status (67).
The UPS is primarily responsible for the degradation of cytosolic, ER, nuclear, and
short-lived proteins. Turnover occurs in a sequential process by which an 8.5 kDa
ubiquitin protein is attached to the protein to be degraded on a lysine residue (67).
Subsequent ubiquitin molecules can be attached to internal residues on ubiquitin itself,
forming an ubiquitin chain that signals the protein to be degraded by the proteasome
(Figure 5.1) (65, 68). However, ubiquitin can also be a signal for certain proteins to be
selectively degraded by autophagy, and it appears that the internal lysine residue of
ubiquitin that serves as an anchor point for additional ubiquitin molecules is the key
player in determining the proteins fate (67). The 26S proteasome is a large ~2.5 MDa
ATP-dependent complex consisting of the 20s catalytic particle (CP) and the 19s
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regulatory particle (RP). The CP is a barrel-shaped structure in which the proteolytic
activity is sequestered and has limited access to proteins destined to be degraded as a
result of gating by other residues. The proteolytic core contains three proteases with
different specificities; acidic residues (caspase-like), basic residues (trypsin-like) and
hydrophobic residues (chymotrypsin-like) (Figure 5.1) (68).
Autophagic degradation has a much broader proteolytic role than proteasomal
degradation in that whole organelles such as mitochondria (mitophagy) or peroxisomes
(pexophagy) can be degraded in addition to individual proteins (67). In the first step of
autophagy a double-membraned structure known as a phagophore surrounds items to
be degraded. As the phagophore is forming, more ‘cargo’ can be added and the
membrane can continue to grow until it becomes an enclosed double-membrane
structure known as an autophagosome, a process that is mediated by several
autophagy-related proteins (Atgs) (Figure 5.2) (69). In the committed step of autophagy,
microtubule-associated protein light chain 3 (LC3-I) is converted to LC3-II via lipidation
with phosphatidylethanolamine and is attached to the autophagosome. The cargoloaded vesicle can then fuse with the lysosome, which contains hydrolases capable of
protein degradation (67). The primary hydrolases present in the lysosomes of
adipocytes are cathepsin B (cysteine protease) and cathepsin D (aspartic protease) (70).
We have identified ~40 succinated proteins and the majority of these are
cytosolic proteins (34). Additionally, we have previously demonstrated that 2SC is
produced endogenously in rats and is excreted in the urine (31), suggesting that there is
an intracellular mechanism that can facilitate the removal of succinated proteins. Due to
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the stability of the thioether bond and that there are no known enzymes that can cleave
the thioether bond, we hypothesized that succinated cytosolic proteins were
predominantly being degraded in the adipocyte by the proteasome. We therefore
investigated the turnover of succinated proteins in the 3T3-L1 adipocyte cultured in high
glucose conditions versus normal glucose to determine if (1) succinated proteins were
being turned over and (2) the mechanism of degradation of succinated proteins.
5.2. Results
The accumulation of succinated proteins in 3T3-L1 adipocytes in 30 mM glucose
is significantly increased at days 4-6 of maturation in association with increased
intracellular concentrations of fumarate (31). As noted in Figure 5.3A, there is an
increase in the levels of 2SC in adipocytes matured in 30 mM glucose compared to 5
mM glucose for 8 days. The reaction of fumarate with cysteine is a non-enzymatic
process, therefore, we next sought to determine if stable succinated proteins could be
removed from within the cell. When adipocytes are matured in 30 mM glucose for 4
days and then switched to 5 mM glucose for the remaining 4 days of maturation, the
levels of 2SC no longer accumulate and are similar to the levels observed in adipocytes
that matured in 5 mM glucose for 8 days (Figure 5.3A). This indicated that there was
intracellular turnover of the succinated proteins that had accumulated up until 4 days.
We then sought to determine specifically when the levels of 2SC began to decline after
removing the high glucose stimulus. As observed in Figure 5.3B, the levels of 2SC began
to decline as early as 1 day after 30 mM glucose removal. In particular there is a greater
reduction in band intensity for proteins with a mass ~30-37 kDa and ~75-100 kDa (Figure
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5.3B). If the 30 mM glucose is replaced with 5 mM glucose for longer time periods, from
1 day up until 4 days, the extent of protein succination is further reduced (Figure 5.3B).
To determine the intracellular mechanism by which the succinated proteins were
being degraded, we next inhibited either the proteasome or the lysosome. MG132 (a
proteasome inhibitor) or chloroquine (a lysosomal inhibitor) were used to attenuate
protein degradation. The adipocytes were matured for 4 days in 30 mM glucose and
then switched to 5 mM glucose -/+ MG132 or chloroquine for the remaining 4 days of
maturation. Figure 5.4A&B confirms that 2SC is increased in adipocytes matured for 8
days in 30 mM and that this is decreased when the high glucose stimulus is removed
after 4 days and replaced with 5 mM glucose for the remaining 4 days (lanes 4-6 vs. 7-9).
For the adipocytes that were switched from 30 mM to 5 mM glucose and
simultaneously treated with 17.5 µM MG132 (lanes 10-12, Figure 5.4A), there was no
accumulation of succinated proteins (Figure 5.4A), suggesting the proteasomal
inhibition does not prevent the degradation of succinated proteins. However, in a
parallel experiment where the adipocytes were switched from 30 mM to 5 mM glucose
and treated with 25 µM chloroquine, succinated proteins did accumulate (lanes 10-12,
Figure 5.4B). This indicated that the lysosome appears to be primarily responsible for
the degradation of succinated proteins. Inhibition of the lysosome was confirmed by the
pronounced increase in LC3-I and LC3-II in chloroquine treated adipocytes compared to
the untreated adipocytes (Figure 5.4B).
Considering that we had established that succinated proteins were being
degraded, we next sought to quantify the release of free 2SC from the adipocyte using
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gas chromatography-mass spectrometry (GC/MS). We measured the basal levels of 2SC
in the Dulbecco’s Modified Eagles Medium (DMEM) and 10% fetal bovine serum (FBS) to
ensure that the 2SC we detected was produced by the adipocyte (rather than measure
any endogenous 2SC in the cell culture reagents). In DMEM, we detected ~0.03 mmol
2SC/mol lysine and in DMEM supplemented with 10% FBS we detected ~0.05 mmol
2SC/mol lysine (data not shown). It has previously been shown that the levels of
fumarate in the cell culture medium increase throughout adipocyte maturation in 25
mM glucose (71). We determined the amount of 2SC present on FBS proteins
(predominantly albumin) when adipocytes were matured in 5 mM or 30 mM glucose in
order to ensure that any free 2SC detected in the maturation medium was being
released from the cells and was not derived from the released fumarate modifying FBS
proteins (Figure 5.5). In order to do this we separated the serum protein from the free
amino acids/peptides released from the cell by trichloroacetic acid precipitation of the
protein in the medium. When the serum protein was analyzed (after it was hydrolyzed
to release free 2SC) there was no difference in the levels of 2SC in the maturation
medium of adipocytes matured in 5 mM or 30 mM glucose on days 4-6, (Figure 5.5).
This indicated that any changes in 2SC could not be attributed to fumarate reacting with
serum proteins in the medium.
Next, we sought to quantify how much 2SC was being synthesized in and
released from the adipocyte itself. Adipocytes were matured in 5 mM or 30 mM glucose
for 8 days, or 30 mM glucose for 4 days then 5 mM glucose for the remaining 4 days -/+
chloroquine. As indicated in Figure 5.6A, there was an ~1.9-fold increase in 2SC in 30
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mM glucose vs. 5 mM glucose in the cell lysate after 8 days of maturation (***p<0.001,
Figure 5.6A). In adipocytes that were switched to normal glucose after 4 days
maturation, there was a significant reduction in 2SC in the cell lysate compared to
adipocytes matured in 30 mM glucose for 8 days (###p<0.001, Figure 5.6A). When the
adipocytes were treated with chloroquine concomitant with the switch to 5 mM glucose
the levels of 2SC were significantly elevated compared to 5 mM glucose (***p<0.001,
Figure 5.6A). We then examined when 2SC was being released from the cells into the
culture medium. Analysis of the culture medium from early maturation days 2-4
revealed a ~1.5-fold increase in 2SC in the medium of adipocytes matured in 30 mM
glucose vs. 5 mM glucose (***p<0.001, Figure 5.6B). As before, on maturation day 4 a
subset of adipocytes were switched from 30 mM to 5 mM glucose for the remainder of
maturation and treated with or without chloroquine. The culture medium from days 4-6
contained ~1.5-fold more 2SC in 30 mM glucose than 5 mM glucose (***p<0.001, Figure
5.6C). Surprisingly, there was no increase in the 2SC in the culture medium of adipocytes
that had been switched from 30 mM to 5 mM glucose (Figure 5.6C), as might be
expected if the 2SC was being degraded intracellularly and released from the cell. The
levels of 2SC in the culture medium of adipocytes that had been treated with
chloroquine were similar to 2SC levels observed in 5 mM glucose (Figure 5.6C),
consistent with chloroquine preventing degradation and release. Culture medium from
late maturation days 6-8 had a similar ~1.3-fold increase in 2SC in adipocytes matured in
high glucose (**p<0.01 and

***

p<0.001 Figure 5.6D). 2SC did not increase in the culture

medium of adipocytes that had undergone the switch from high to normal glucose on
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days 6-8 (Figure 5.6D). Unexpectedly, the adipocytes that had been treated with
chloroquine had a ~1.6-fold increase in 2SC in the culture medium on days 6-8 vs.
adipocytes matured in normal glucose for 8 days (***p<0.001, Figure 5.6D).
The above measurements demonstrated that free 2SC was detectable in the
culture medium. However, the hydrolysis step in preparation for GC/MS analysis did not
allow us to differentiate whether the 2SC was released as a free modified cysteine or as
part of a small peptide incorporating the 2SC. We examined the culture medium of
adipocytes matured in normal or high glucose on days 4-6. The samples were divided
into two equal parts after removal of the serum proteins, one part being subjected to
hydrolysis to determine the total amount of 2SC, and the other not hydrolyzed
representing the amount of free 2SC released from the adipocyte. As observed in Figure
5.7, there was ~0.039 mmol 2SC/mol lysine total in the culture medium while there was
0.008 mmol 2SC/mol lysine detected as free 2SC in the culture medium in adipocytes
matured in 5 mM glucose. In adipocytes matured in 30 mM glucose there was 0.09
mmol 2SC/mol lysine total in the culture medium while 0.04 mmol 2SC/mol lysine is
liberated as free 2SC. The difference in the total 2SC and that detected as free 2SC
(detected in the absence of peptide hydrolysis) represents the fraction that is peptide
bound, demonstrating that 2SC is released both as a free amino acid and as part of a
peptide.
5.3. Discussion
The formation of S-(2-Succino)cysteine (2SC) is an irreversible chemical
modification as the reaction of fumarate with cysteine forms a thioether bond, which is
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very stable, and there are no known enzymes that can cleave this bond. Protein
succination is increased in 3T3-L1 adipocytes that have been matured 30 mM glucose vs.
5 mM glucose (Figure 5.3, 5.4 and 5.6) and in the adipose tissue of ob/ob and db/db
mice (32). We were interested in determining if and how succinated proteins were being
degraded in the adipocyte as we had previously shown that rats excreted 2SC in their
urine (31), indicating turnover occurred in vivo. We observed that adipocytes matured in
high glucose for 4 days that were then switched to normal glucose for the remaining 4
days of maturation had levels of succination similar to cells that had matured in normal
glucose for 8 days, indicating that accumulated succinated proteins can be degraded
intracelluarly (Figure 5.3A). We used the proteasomal inhibitor, MG132, and the
lysosomal inhibitor, chloroquine, to determine which intracellular protein degradation
pathway was responsible for the turnover of 2SC. In the presence of MG132, succinated
proteins did not accumulate (Figure 5.4A) suggesting the proteasome was not involved.
In contrast, when the adipocytes were switched to normal glucose in the presence of
chloroquine, turnover of succinated proteins was prevented (Figure 5.2B), indicating
that the lysosome was responsible for the degradation of succinated proteins. This
conflicted with our original hypothesis, as we predicted the proteasome would be
responsible for degrading succinated proteins considering that we had primarily
identified succinated cytosolic and ER proteins (34). However, this data is interesting
considering that autophagy is responsible for removal of damaged organelles such as
mitochondria (mitophagy). It will be important in future studies to look at the turnover
of specific organelle containing fractions by the lysosome.
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The analysis of the 2SC content in the cell lysates and culture medium by GC/MS
(Figure 5.6A-D) indicated that levels of succinated proteins in adipocytes matured in 30
mM glucose were always significantly increased compared to 5 mM glucose. We were
able to detect 2SC in the culture medium at all time points from days 2-8 indicating the
turnover of some fraction of succinated proteins appears to be a continuous process in
adipocytes matured in both 30 mM and 5 mM glucose. We also demonstrated that 2SC
is released from the adipocyte both as a free amino acid and as part of a peptide, as
indicated by the differences in the levels of 2SC that were detected when the samples
were prepared -/+ hydrolysis to release the 2SC (Figure 5.7).
When adipocytes are matured in high glucose and then switched to normal
glucose, the levels of succinated proteins are significantly reduced compared to
adipocytes that matured in high glucose for 8 days (Figure 5.6A). Analysis of the 2SC
content in the culture medium of these adipocytes from days 4-6 and days 6-8 did not
show an increase in the levels of 2SC released from the cell, which was unexpected as
the intracellular levels of 2SC had been reduced close to normal levels. During the
workup process of the cell lysate, the proteins are precipitated with 10% TCA and free
amino acids and peptides remain the supernatant and this was not analyzed for the cell
lysates. It is possible that the ‘missing’ 2SC had been degraded into peptides and amino
acids, but had not yet been released into the medium by the cell and therefore was not
detected.
In adipocytes that had been treated with chloroquine, the degradation of 2SC
was prevented as indicated by the sustained levels of 2SC even when the high glucose
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stimulus is removed (Figure 5.4B & 5.6A). The analysis of the culture medium on days 46 did not show a significant increase in the amount of 2SC compared to 5 mM glucose,
indicating that the degradation of 2SC modified proteins had been prevented. However,
the culture medium from days 6-8 indicated a significant increase in the levels of 2SC
(Figure 5.6D) which was not expected when the lysosome is inhibited. We suspect that
prolonged inhibition of the lysosome may alternatively up-regulate proteasomal activity,
thereby degrading proteins that may not normally be degraded by that pathway and
contributing to the detected increase in 2SC (72).
It is worth noting that although adipocytes matured in 5 mM glucose could
produce more 2SC had they of been matured in 30 mM glucose (Figure 5.6A), there is
still degradation of the basal levels of 2SC present in the adipocytes (Figure 5.6B-D),
demonstrating that autophagy is constantly occurring in the adipocyte. We have
preliminary data suggesting that autophagy is impaired in adipocytes matured in 30 mM
glucose which may explain adipocyte dysfunction when in high glucose. Mitophagy has
been shown to be an important process involved in the differentiation of 3T3-L1
fibroblasts into 3T3-L1 adipocytes as atg5-/- and atg7-/-deficient MEFs have reduced
adipogenesis efficiency as noted by defective lipid droplet formation and compromised
TG synthesis (73). However, as our adipocytes proceed through differentiation normally
in both 5 mM and 30 mM glucose (as indicated by the PPARγ and adiponectin
production (Figure 2.3A)) autophagy is unlikely impaired at this stage. Interestingly, in
3T3-L1 adipocytes matured in high glucose, autophagy was suppressed and mRNA levels
of pro-inflammatory cytokines were elevated (74) as were the levels of secreted
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cytokines (Figure 2.4), suggesting that impaired autophagy is associated with adipocyte
dysfunction.
In conclusion, we have shown that 2SC modified proteins are degraded through
autophagy in the adipocyte. This is in contrast to our original hypothesis that the
proteasome would be involved. We are currently studying the degradation of 2SC in
different cellular compartments to examine if the location of succinated proteins within
the cell determines the degradation pathway. In addition, we are interested in
determining whether or not adipocytes matured in high glucose are undergoing
autophagy at a different rate to adipocytes matured in 5 mM glucose. Therefore future
studies will examine autophagic flux within the cell to determine the kinetics of
succinated protein turnover.
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Figure 5.1. Schematic of protein degradation by the ubiquitin proteasome system.
Misfolded or aggregated proteins are ubiquitinated in an ATP-dependent manner. The
ubiquitinated protein is recognized by the proteasome which then degrades that protein
into its constituent parts and recycles the ubuiquitin molecules for marking other
proteins for degradation (65).
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Figure 5.2 Induction of autophagy and lysosomal degradation. Schematic of autophagic
degradation from phagophore formation to autophagolysosome formation. Atgs assist
in the formation of the autophagic vesicle and Atg3 and Atg7 mediate lipidation of LC3-I,
forming LC3-II which is incorporated in the autophagosomal membrane (66).
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Figure 5.3. Time course of the turnover of succinated proteins. (A) Adipocytes were
matured in 5 mM or 30 mM glucose for 8 days. A subset of adipocytes was matured in
30 mM glucose for 4 days then switched to 5 mM glucose for the remaining 4 days.
Protein (40 µg) was separated by 1-D PAGE and succinated proteins were detected using
a polyclonal anti-2SC antibody (B) Adipocytes were matured in 5 mM or 30 mM glucose
for 8 days. A subset of adipocytes were switched from 30 mM glucose and replaced with
5 mM glucose for 4, 3, 2, or 1 remaining days of maturation (30→5). Protein (30 µg) was
separated by 1-D PAGE and 2SC was detected using a polyclonal anti-2SC antibody to
detect the presence of succinated proteins. Molecular weight (MW) markers (kDa) are
shown as a reference for the range in MW of succinated proteins.
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Figure 5.4. Turnover of succinated proteins. Adipocytes were matured in 5 mM or 30
mM glucose for 8 days. A subset of adipocytes were matured in 30 mM glucose for 4
days and then switched to 5 mM glucose for the remaining 4 days of maturation
(30→5). They were then treated with or without (A) 17.5 µM MG132 or (B) 25 µM
chloroquine. Protein (A) 30 µg and (B) 40 µg was separated by 1-D PAGE and detection
of 2SC was performed using a polyclonal anti-2SC antibody. Western blotting for LC3
was assessed to confirm inhibition of lysosomal degradation. MW markers are shown in
kDa and β-Tubulin is shown to demonstrate equal protein loading.
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Figure 5.5. Modification of serum proteins by succination. 3T3-L1 adipocytes were
matured in 5 mM or 30 mM glucose. The maturation medium was collected from the
adipocytes on maturation days 4-6 and serum protein was TCA precipitated and
analyzed by GC/MS for 2SC and lysine content. The 2SC content was normalized to the
lysine content of the sample. Data are representative of n=4-5 measurements expressed
as means ± S.D. Data were tested for statistical significance using an unpaired Student t
test.
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Figure 5.6. GC/MS analysis of 2SC content in adipocyte cell lysate and culture medium.
Adipocytes were matured in 5 mM or 30 mM glucose for 8 days. A subset of adipocytes
was matured in 30 mM glucose for 4 days and then switched to 5 mM glucose for the
remaining 4 days (30→5) and treated with or without chloroquine (CQ). (A) On day 8,
the cells were harvested and the levels of intracellular succinated proteins was
determined in the cell lysate by GC/MS. Medium was collected from days (B) 2-4, (C) 4-6
and (D) 6- 8 of maturation and analyzed by GC/MS for 2SC content. Data are
representative of n=5 measurements expressed as means ± S.D. Statistical significance
was determined using a One Way ANOVA and Tukey’s post hoc test (*P<0.05 **P<0.01
and ***P<0.001 for 30 mM glucose or 30 to 5mM ±CQ vs. 5 mM glucose and ###P<0.001
for 30 mM vs. 30 to 5 mM. Gray bars ( 5 mM), black bars (30 mM), striped bars (30 mM
to 5 mM), and checkered bars (30 mM to 5 mM + CQ)).
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Figure 5.7: Release of 2SC as an amino acid or in a peptide. 3T3-L1 adipocytes were
matured in 5 mM or 30 mM glucose. The medium from days 4-6 of maturation was
analyzed for total and free 2SC content by GC/MS. Data are representative of n=3
measurements expressed as means ± S.D. Asterisks indicate statistical significance as
determined by a paired Student t test (*P<0.05 and ***P<0.001. Black bars (total 2SC in
5 mM glucose), light gray striped (free 2SC in 5 mM glucose), gray bars (total 2SC in 30
mM glucose), and gray striped bars (free 2SC in 30 mM glucose)).
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Chapter VI
Future Directions
We are interested in continuing our investigation into the role of ER stress in the
development of T2DM and plan to examine human adipose tissue and determine if
protein succination is increased in T2DM subjects. We are also interested in alternative
chemical agents/uncouplers that may reduce protein succination as they may be
therapeutically beneficial in treating T2DM.
Our results on the turnover of succinated proteins by autophagy were
unexpected and intriguing. Consequently, we are interested in the role of autophagy in
adipocyte pathology during T2DM. Our preliminary data suggests that autophagy may
be dysfunctional in adipocytes matured in high glucose and interestingly, if the
adipocytes are switched to normal glucose there is restoration of autophagic function.
We have identified cathepsin B as a protein that is succinated at its active site, Cys-108
(34), so it will be of interest to determine if the activity of Cathepsin B is reduced and
whether or not this affects lysosomal function in the adipocyte. We are also interested
in another autophagy protein, Atg7, as the active site also contains a cysteine residue
(75), and this may as also affect the rate of autophagy if succinated. Atg7 is one of the
proteins that lipidates LC3-I, committing the autophagosome to fuse with the lysosome.
Lastly, as we have identified 2SC as a novel protein modification that is increased
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in diabetes, were are interested in continuing to investigate the biochemical mechanism
by which this leads to adipocyte dysfunction. We have identified over 40 succinated
proteins (34) and we still have to examine the significance of many of these identified
sites and to determine if and how the function of these 2SC modified proteins is
affected in T2DM.
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Chapter VII
Methods
Materials. Unless otherwise noted, all chemicals were purchased from Sigma Aldrich (St.
Louis, MO). Preparation of 2SC antibody was prepared by Eurogentec (Fremont, CA)
Sodium phenylbutyrate (PBA) was from Enzo Life Sciences (Farmingdale, NY) for in vitro
studies and Scandinavian Formulas Inc. (Sellersville, PA) for in vivo studies.
Polyvinylidene fluoride (PVDF) was purchased from GE Healthcare (Farifield, CT). Lglycine, sodium dodecyl sulfate (SDS), sodium salicylate (SA), and Tween-20 were
purchased from Fisher Scientific (Waltham, MA).

For in vitro studies insulin was

purchased from Bio Ab Chem (Ladson, SC). For in vivo studies insulin was purchased
from Sigma Aldrich (St. Louis, MO). For in vitro studies glucose oxidase was from
Invitrogen (Grand Island, NY) and for in vivo studies glucose oxidase was from Raichem
(San Marcos, CA). Criterion™TGX™ Precast Gels were from Bio-Rad (Hercules, CA). The
CyQuant® assay was from Invitrogen (Grand Island, NY). All materials for the Seahorse
XF24 were purchased from Seahorse Bioscience (North Billerica, MA) except pyruvate,
glucose, insulin, and mitochondrial inhibitors.
Animal Models. Male C57BL/6 mice were purchased from Jackson Laboratories (Bar
Harbor, ME). Mice were obtained at 5-6 weeks of age and allowed to acclimate 1-2
weeks with unrestricted access to food and water before experimental manipulations
began.
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PBA was administered in the drinking water at a dosage of 1 mg/g BW/day for
the first 3 weeks and was reduced to 0.5 mg/g BW/day for the remaining 4 weeks of the
study. Animals were sacrificed at 15 weeks of age. Blood glucose measurements were
performed weekly after an overnight fast by collecting tail vain blood using a Bayer
(Whippanny, NJ) Countour® blood glucose meter for control animals and the glucose
oxidase assay for db/db mice.
Water and food consumption was measured biweekly. All animal handling and
experiments were conducted according to the guidelines of the University of South
Carolina Institutional Animal Care and Use Committee. Animals were sacrificed using
CO2 asphyxiation and epididymal adipose tissue was removed and rinsed in PBS with
protease inhibitors and frozen on dry ice. Livers were removed and immediately frozen
on dry ice.
Body Composition. Body composition was measured at 14 weeks using a Dual Energy Xray Absorptiometry scan under isoflurane anesthesia, measuring fat and lean content.
Insulin Tolerance Test. Insulin tolerance tests were performed at 14 weeks of age on all
mice. The mice were fasted starting the morning of the test for 4.5 hours. Insulin was
injected intraperitoneally, 2 U. Blood was collected by tail vein at time 0, 15, 30, 60, 90,
and 120 minutes after injection of insulin. Blood glucose was measured in control
animals using a Bayer (Whippanny, NJ) Countour® blood glucose meter. In db/db mice,
the glucose oxidase assay was used to measure serum blood glucose levels.
Protein Extraction from Adipose Tissue. Adipose tissue was added to 2.5 mL ice-cold
radio immunoprecipitation assay buffer (RIPA) buffer and sonicated 3 times for 12-15
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seconds each. The tissue sat on ice for 30 minutes and was then centrifuged at 2800 g
for 10 minutes at 4 oC. A pellet, infranatant and supernatant were then visible. The
infranatant, up to 1.5 mL was then collected using a needle and syringe. Acetone, 9X
volume, was then added to the samples, vortexed, then let sit on ice for 10 min. The
samples were then centrifuged at 2800 g for 10 minutes at 4oC. The acetone was
decanted and the samples let air dry for 10 min on ice. The samples were then
resuspended in 0.5 – 1 mL of radio RIPA buffer and sonicated 3 times for 10 seconds
each. The samples were then centrifuged at 15000 rpm for 10 min at 4 oC yielding an
infranatant and a fat layer. The infranatant was collected and the protein concentration
was determined using the Lowry assay.
Protein Extraction from Liver Tissue. Liver tissue was added to 2 mL ice-cold RIPA buffer
and sonicated 2 times for 10-15 seconds each and was then centrifuged at 2800 g for 10
minutes at 4 oC. A pellet, infranatant and supernatant were then visible. The infranatant,
up to 1.5 mL was then collected using a needle and syringe. Acetone, 9X volume, was
then added to the samples, vortexed then let sit on ice for 10 min. The samples were
then centrifuged at 2800 g for 10 minutes at 4oC. The acetone was decanted and the
samples let air dry for 10 min on ice. The samples were then resuspended in 1 mL of
RIPA buffer and sonicated 3 times for 10 seconds each. The samples were then
centrifuged at 15000 rpm for 10 min at 4 oC yielding an infranatant and a fat layer. The
infranatant was collected and the protein concentration was determined using the
Lowry assay.
Triglyceride Extraction from Liver Tissue. Liver tissue was added to ice-cold PBS with
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protease inhibitors and sonicated 3 times for 10 seconds each. 300 μL of sample was
then extracted using 8:4 chloroform:methanol. The samples were vortexed, then let sit
on ice for 10 min followed by centrifugation at 2000 g for 10 min at 4 oC. Three layers
formed with the protein interface dividing the infranatant and supernatant. The
infranatant was collected and was dried under air. The samples were resuspended in 5%
BSA and triglyceride concentration was determined using InfinityTM Triglycerides assay
kit (Thermo Fisher Scientific, Waltham, MA), according to the manufacturer’s
instructions.
Cell Culture. 3T3-L1 murine fibroblast were purchased from American Type Culture
Collection (Manassas, VA) and maintained up to 8 passages in DMEM containing 5 mM
glucose, 10% Bovine Calf Serum (Thermo Scientific), 1% penicillin/streptomycin (CellGro)
at 37oC with 5% CO2 and 95% humidity. Medium was changed every 2 days. At 70-80%
confluence cells were trypsinized (Thermo Scientific), neutralized with excess medium
and collected by centrifugation at 1000 g for 5 min at 25 oC. The cells were then
resuspended in medium for a new passage.
3T3-L1 fibroblasts were seeded at densities of 10,000, 50,000, and 100,000
cells/well for 24-well, 6-well plates and 10 cm2 petri dishes respectively. 3T3-L1
fibroblasts were induced to differentiate when the fibroblast reached 24 hours postconfluence (~3-4 days) in DMEM with 10% Fetal Bovine Serum (Atlanta Biologicals), 1%
penicillin/streptomycin, insulin (10 μg/mL), dexamethasone (0.3 μM), 3-isobutyl-1methylxanthine (0.5 mM) and 30 mM glucose for 3 days. At day 0, differentiation
medium was removed, cells were washed with PBS and maturation medium containing
83

5 mM/0.3 nM or 30 mM/3 nM glucose/insulin was applied. The medium was changed
every 2 days and the adipocytes were matured for up to 8 days. Cells cultured in 5 mM
glucose were supplemented with 5mM glucose daily and several hours prior to protein
harvest to maintain glucose levels.
Measurement of triglycerides, glucose, and inflammatory markers in 3T3-L1
adipocytes. Triglyceride content was measured in 10 µl aliquots of cell lysates using the
InfinityTM Triglycerides assay kit (Thermo Fisher Scientific, Waltham, MA), according to
the manufacturer’s instructions. Glucose concentration was measured in phenol red
free medium using the Amplex® Red Glucose/Glucose Oxidase Assay kit (Invitrogen,
Grand Island, NY). The media on 3T3-L1 adipocytes was replaced with serum-free
DMEM for 18 hrs. Pro-inflammatory cytokines in the conditioned media were analyzed
by ELISA according to the manufacturer’s instructions (mouse Obesity ELISA, Signosis,
Santa Clara, CA).
DNA isolation and mitochondrial content analysis. Cell lysates were collected in 500 µL
PBS, centrifuged at 2000 rpm for 5 min to yield a pellet which was resuspended in 350
µL DNA lysis buffer (10 mM Tris-HCl, pH7 7.5, 400 mM NaCl, 2.5 mM EDTA , and 0.1%
SDS), 50 µL of 50 mg/mL proteinase K and heated at 55°C overnight. The tubes were
inverted to dissolve any remaining solid then extracted in a 1:1 ratio of lysis
buffer:saturated phenol, pH 7.9. The samples were then centrifuged at 15000 rpm for 5
min,

the

supernatant

was

collected

and

extracted

in

a

1:1

ratio,

supernatant:phenol/chloroform/isoamyl alcohol (25:24:1), pH 7.9 then centrifuged at
15000 rpm for 5 min. The supernatant was collected and the DNA was precipitated with
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350 µL 100% ethanol and 35 µL of 3 M sodium acetate, pH 5.2, and collected by
centrifugation at 15000 rpm for 2 min. The DNA pellet was washed with 70% ethanol,
dried, then resuspended in 100 µL water. The samples were stored at -20°C until PCR.
Quantitative real-time PCR analysis was carried out in 25 μl reactions consisting
of 2x SYBR green PCR buffer (AmpliTaq Gold DNA Polymerase, Buffer, dNTP mix, MgCl2)
(Applied Biosystems, Foster City, CA, USA), 0.150 μg DNA, DI water, and 60 nM of each
primer. PCR was run with the DNA sample with Cytochrome B Forward, 5′ - ATT CCT TCA
TGT CGG ACG AG −3′; Cytochrome B Reverse, 5′ - ACT GAG AAG CCC CCT CAA AT - 3′,
GAPDH Forward, 5′ - TTG GGT TGT ACA TCC AAG CA - 3′; GAPDH Reverse, 5′ - CAA GAA
ACA GGG GAG CTG AG - 3′. Samples were analyzed on an ABI 7300 Sequence Detection
System. Reactions were incubated for 2 minutes at 50°C and 10 minutes at 95°C,
followed by 40 cycles consisting of a 15 sec denaturing step at 95°C and 1 min
annealing/extending step at 60°C. Data were analyzed by ABI software (Applied
Biosystems, Foster City, CA, USA) using the cycle threshold (CT), which is the cycle
number at which the fluorescence emission is midway between detection and
saturation of the reaction. The 2-Δ CT method was used to determine changes in gene
expression between Cytochrome B with GAPDH CT as the correction factor.
Protein Extraction from Cells. All samples and reagents were kept on ice during protein
harvest. The cells were washed 3 times with phosphate buffered saline (PBS). The cells
were collected in RIPA buffer and pulse sonicated at 2 watts for 3 intervals of 3 seconds.
Acetone was then added in 9 times the volume, the samples were vortexed then let
precipitate on ice for 10 minutes. The protein was collected by centrifugation at 2000 g
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for 10 minutes at 4oC yielding a white to pale yellow protein pellet. The supernatant was
decanted and the pellet let air dry for 10 minutes on ice. The protein was resuspended
in RIPA buffer and pulse sonicated for 3 intervals of 3 seconds. The samples were stored
at -70oC until further analysis.
Western Immunoblotting. Samples were prepared using 25-40 µg for cell lysates and
40-100 μg for mice tissue with the addition of 5-7 μL 4X Laemmli loading buffer. The
samples were then boiled at 95oC, flash centrifuged then loaded on 7.5%, 12% or 18%
gels and electrophoresed at 200 V for 60 min. The protein was transferred to a PVDF
membrane in transfer buffer at 250 mA for 100 min or 40 mA at 4 oC. The membrane
was ponceau stained then blocked in 5% non-fat milk or 5% bovine serum albumin (BSA)
according to the manufacturer’s instructions. Membranes were probed using primary
polyclonal anti-2SC. Antibodies for ACC, p-ACC, calreticulin, cleaved caspase-3, eIF2α, peIF2α, Ero1-Lα, FAS, fumarase, LC3, and succinate dehydrogenase were from Cell
Signaling. Adiponectin was from R&D Systems. CHOP was from Thermo Scientific.
NDUSF4 was from AbCam. β-tubulin, Grp78 and PDI were from Santa Cruz. Pierce® ECL 2
Western Blotting Substrate or Amersham™ ECL™ Prime Western Blotting Detection
Reagent (GE Healthcare) was used and followed by detection of chemiluminescence
using photographic film (Denville Scientific, Metuchen, NJ). Image J software (NIH) was
used to quantify band intensity by densitometry.
GC/MS Analysis of 2SC. 3T3-L1 adipocytes were matured as described in cell culture.
The cell culture medium from adipocytes was collected on days 4, 6 and 8 of maturation
and frozen at -70°C until further analysis. Adipocytes were harvested for protein after 8
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days of maturation as described in protein harvest. DMEM and culture medium were
extracted in an 8:4:3 chloroform/methanol/water ratio. The samples were vortexed and
let precipitate on ice for 10 min followed by centrifugation at 2000 g for 10 min at 4 oC.
Three layers formed, with the protein interface (albumin) separating the organic
(bottom) and water/methanol (top) layer. The water/methanol layer was collected and
the contents were dried overnight on a speedvac. The samples were resuspended in 600
μL water and sonicated, extraction was re-performed and the samples were dried
overnight.
Cell lysates were extracted in a 1:1 ratio with 20% (w/v) trichloroacetic acid,
vortexed, let precipitate on ice for 10 min then centrifuged at 2500 g for 5 min at 4oC
yielding a pellet and supernatant. The pellet was resuspended in 500 μL 10% (w/v) TCA
and let precipitate on ice for 10 min then centrifuged at 2500 g for 5 min at 4oC yielding
a protein pellet.
To each sample 75 nmol D8-Lys, 0.375 nmol heavy labeled-2SC and 1 mL 12 N
HCl was added, followed by overnight hydrolysis at 110oC. The samples were then dried
overnight on the speedvac. The samples were resuspended in 1 mL of 1% trifluoroacetic
acid (TFA), sonicated, and passed over a C-18 SepPak column pre-wet with 2 mL
methanol and 2 mL 1% TFA. The analyte was eluted with 20% methanol/1% TFA and
dried overnight on the speedvac. To each sample was then added methanolic HCl,
followed by vortexing, heating for 45 min at 65°C then dried under air. Trifluroacetic
acid anhydride was then added, 1 mL, to each sample, and let sit for 1 hr at room
temperature, then dried under air for ~15 min. Dichloromethane, 200 µL, was then
87

added to the samples before being centrifuged at 10,000 g for 5 min at 25oC. The
samples were then concentrated under air.
Samples were analyzed by multiple reaction monitoring GC-MS/MS on a TSQ
7000 (Thermo-Finnigan, Waltham, MA). The injection port was maintained at 200 °C,
and the temperature program was 90 °C hold for 2 min, 10 °C/min from 90 to 140 °C, 3
°C/min to 220 °C, 15 °C/min to 300 °C, then hold at 300 °C for 5 min. The parent and
daughter ion pairs monitored were: lysine m /z 180 > 69, d8 -lysine, m /z 188 > 69; 2SC,
m /z 284 > 242, U-13 C3 ,15 N-2SC m /z 288 > 246. Quantification of analytes in protein
samples was performed by isotope dilution mass spectrometry based on standard
curves constructed from mixtures of known amounts of heavy labeled and natural
abundance standard. The amounts of all analytes were normalized to the lysine content
of the sample.
Seahorse Extracellular Flux Analyzer 24. 3T3-L1 murine fibroblast were seeded 10,000
cells/well in a 100 μL volume on XF24 V7 microculture plates coated with 0.2% gelatin
(Sigma, porcine skin, Type A, Batch # 014K0077). The next day, 150 μL of medium was
added to the cells. Fibroblasts grew for 3 days followed by differentiation and 2 days of
maturation.
The night before the assay, an XF calibrant cartridge was hydrated overnight in
XF calibrant, pH 7.4 at 37oC with 0% CO2. The day of the assay, the medium was
removed, the adipocytes were washed with 1 mL of XF Assay Buffer, pH 7.4, followed by
application of 600 μL XF Assay medium, pH 7.4, supplemented with 1%
penicillin/streptomycin, 1 mM sodium pyruvate, 5 mM/0.3 nM or 30 mM/3 nM
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glucose/insulin, and incubation for 60-90 min at 37oC with 0% CO2. Injections were
added in a 1:9 volume in the following order: blank, oligomycin (5 µg/mL), carbonyl
cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) (1.25 µM), rotenone/antimycin A
(3 µM/4 µM). Assay conditions involved a mixing (3 min), a wait (2 min), and a measure
(3 min) after addition of the blank, oligomycin and rotenone/antimycin A (3 µM/4 µM)
and PBA. For FCCP, the conditions were a mixing (2 min) followed by a measurement (2
min). For SA, the conditions were mixing (4 min), wait (2 min), followed by a
measurement (2 min).
Following the assay the cells were washed with PBS and stored at -70oC. The DNA
content was quantified using the CyQuant® assay according to the manufacture’s
protocol.
Data Analysis. All graphs were generated in Sigmaplot 11. Statistical analyses of the
data were performed on SigmaStat software (Sigmaplot 11, San Jose, CA). All data were
plotted as means ± SD. An unpaired Student t test was used to test for statistical
differences between two sets of data, except in Figure 5.7 where an unpaired t test was
used. A One Way ANOVA using Tukey’s post hoc test was used when comparing 3 or
more sets of data. A Kruskal-Wallis One Way Analysis of Variance on Ranks was used for
data not normally distributed. FBG and serum TGs were tested for statistical differences
using a Two Way Repeated Measures ANOVA (One Factor Repetition). Differences were
considered statistically significant at *p<0.05, **p<0.01 and ***p<0.001.
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Appendix A
Buffer Preparations

RIPA Buffer
The buffer was prepared in 200 mL stocks containing 50 mM Tris-HCl pH 8, 150 mM
NaCl, 1% Triton-X, 0.5% sodium deoxycholate, 0.1% SDS, and 2 mM EDTA. On day of use,
2 mM sodium orthovanadate, 2 mM sodium fluoride and protease inhibitor (1:1000)
was added to the buffer. The buffer was stored at 4oC.
Running Buffer
One liter of 10x stock was prepared containing 250 mM Tris-HCl, 1920 mM glycine and
10% (SDS).
Transfer Buffer
One liter of 10X stock was prepared containing 250 mM Tris-HCl, 1920 mM glycine.
Methanol was added at 20% for transfer process.
Wash Buffer
One liter of 10X stock was prepared containing 200 mM Tris-HCl, pH 7.4. Tween-20 was
added at 0.05% to 1X was buffer.
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Appendix B:
Lowry Assay
Pipette the specific amounts of reagents into the microplate in the order listed. All
samples are prepared in duplicates.
Table B.1: Preparation of BSA standard curve for the Lowry assay.
Copper
Reagent
(µL)
20
20
20
20
20
20
20
20
20

Incubation

FolinCiocolateu
(µL)
60
60
60
60
60
60
60
60
60

Incubation

30 minutes at 37oC

H20
(µL)
20
19
18
17
16
12
10
0
15

20 minutes at 37oC

Probe
Blank
1
2
3
4
5
6
7
Sample

BSA
(µL)
0
1
2
3
4
8
10
20
5

Stock BSA
Dissolve 50 mg BSA (Bovine Serum Albumin) in 10 mL deionized water=5 mg/mL
stock/working solution
Working Solutions: Dilute 400 µL of 5 mg/mL stock in 600 µL water=2 mg/mL solution
Table B.2: Preparation of copper reagent for Lowry assay.
Stock Solution
Copper Sulfate 1% (w:v)
Sodium Tartrate 2% (w:v)

Working Solution
100 µL
100 µL

Sodium Carbonate 10% (w:v) in 0.5 M NaOH

2 mL

Folin-Ciocolateu Phenol Reagent: Purchased as a 2 N stock solution. For working
solution at 500 µL of stock solution to 5.5 mL of water
Read absorbance at 660nm.
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Appendix C
Western Blotting

Gel Electrophoresis
1. After determining the protein content from the Lowry assay, 30-40 µg of protein was
dissolved in water and 5 µL of Laemmli loading buffer was added.
2. Boil the samples for 15 min at 95°C then flash centrifuge.
3. Remove tape and comb from Bio-Rad pre cast Criterion gel and place in cassette.
4. Fill the cassette tank and gel with Tris/Glycine/SDS running buffer.
5. Load the samples into their individual lanes and 8 µL of marker into your lane of
choice.
6. Run the gel at 200 V for 60 min.
Wet Transfer
1. Remove the gel from the pre-cast and cut to size
2. Soak the gel in Tris/Glycine/Methanol transfer buffer for 15 min.
3. Charge the PVDF membrane for ~30 sec in methanol. Soak the 2 pieces of blotting
paper, 2 sponges, and the membrane in Tris/Glycine/methanol for 15 min.
4. Assemble the transfer apparatus, starting with the black side first. Keep all materials
soaking in transfer buffer during the assembly.
5. Place the sponge flat on the black side, followed by a piece of blotting paper. Next,
place the gel on top followed by the PVDF membrane. Roll out any air bubbles between
the gel and membrane using a roller. Finally, put the remaining piece of blotting paper
on top of the membrane and the sponge on top.
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6. Assemble the apparatus and transfer at 250 mA for 100 min or 40 mA for at least 12
hrs.
7. Remove the membrane from the apparatus and wash 3 times with nanopure water.
8. Place the membrane in ponceau stain for 5 min then wash with nanopure water to
visualize the bands. Inspect the membrane for equal loading and where bubbles formed
during the transfer process. Wash the ponceau stain off the membrane with Tris-HCl
wash buffer.
9. Block the membrane in 5% non-fat dry milk or 5% BSA for at least 1hr.
Immunostaining for 2SC
1. Prepare 1% milk by diluting the 5% milk 1:4 in Tris-HCl wash buffer.
2. Add 2SC antibody to the milk in a 1:5000 dilution. Incubate for at least 1 hr on the
rocker.
3. Pour off the antibody and wash the membrane 3 times in wash buffer for 5 min each.
4. Add secondary antibody anti-rabbit to 1% milk, 1:15000 dilution and incubate for 1hr
at room temperature.
5. Pour off the milk and was the membrane 3 times for 5 min each in wash buffer.
Developing
1. Prepare ECL solution by adding solution B to solution A and in a 1:40 dilution.
2. Add the ECL to the membrane and incubate for 5 min. Place the membrane in the
cassette and cover with plastic wrap.
3. In the dark room, place a piece of X-ray film over the membrane then develop.
Inspect the film after it has developed and adjust the exposure times accordingly.
Buffers
1. Stock Running Buffer: 10X SDS – 30.3 g Tris base, 144 g glycine and 10 g SDS
dissolved to 1 L water
- Working solution=100mL of 10X stock diluted to 1L water
2. Stock Transfer Buffer: 10X transfer – 30.3 g Tris base and 144 g glycine dissolved to 1
L water
- Working solution=150 mL of 10X stock and 300 mL of methanol diluted to 1 L
water
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3. Stock Wash Buffer: 10X Wash – 24.4 g Tris base dissolved to 1 L water, pH 7.4
- Working solution=100 mL of 10X stock and 500 µL Tween-20 diluted to 1 L water
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